Baxter International (BAX) 10-Q 30 Oct 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 28, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	30-Sep-13
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Trading Symbol	BAX
Entity Registrant Name	BAXTER INTERNATIONAL INC
Entity Central Index Key	10456
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		542,697,603

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Income (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net sales	$3,774	$3,477	$10,891	$10,437
Cost of sales	1,828	1,667	5,250	5,041
Gross margin	1,946	1,810	5,641	5,396
Marketing and administrative expenses	984	743	2,617	2,284
Research and development expenses	290	290	809	865
Net interest expense	45	25	87	65
Other (income) expense, net	-55	-14	10	-133
Income before income taxes	682	766	2,118	2,315
Income tax expense	138	183	432	483
Net income	$544	$583	$1,686	$1,832
Net income per common share
Basic	$1	$1.07	$3.10	$3.32
Diluted	$0.99	$1.06	$3.06	$3.29
Weighted-average number of common shares outstanding
Basic	543	548	543	552
Diluted	549	552	550	556
Cash dividends declared per common share	$0.49	$0.45	$1.43	$1.12

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net income	$544	$583	$1,686	$1,832
Other comprehensive income, net of tax:
Currency translation adjustments, net of tax expense of $19 and $18 for the three months ended September 30, 2013 and 2012, respectively, and $15 and $20 for the nine months ended September 30, 2013 and 2012, respectively	112	180	58	-41
Pension and other employee benefits, net of tax expense of $23 and $18 for the three months ended September 30, 2013 and 2012, respectively, and $67 and $57 for the nine months ended September 30, 2013 and 2012, respectively	42	28	119	101
Hedging activities, net of tax expense (benefit) of $0 and ($10) for the three months ended September 30, 2013 and 2012, respectively, and $11 and ($10) for the nine months ended September 30, 2013 and 2012, respectively	-2	-18	21	-17
Other, net of tax expense (benefit) of $5 and ($1) for the three months ended September 30, 2013 and 2012, respectively, and $5 and ($1) for the nine months ended September 30, 2013 and 2012, respectively	13	-2	12	-1
Total other comprehensive income, net of tax	165	188	210	42
Comprehensive income	$709	$771	$1,896	$1,874

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Tax expense on currency translation adjustments	$19	$18	$15	$20
Tax expense on pension and other employee benefits	23	18	67	57
Tax expense (benefit) on hedging activities	0	-10	11	-10
Tax expense (benefit) on other	$5	($1)	$5	($1)

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Current assets
Cash and equivalents	$2,376	$3,270
Accounts and other current receivables, net	2,766	2,425
Inventories	3,581	2,803
Prepaid expenses and other	874	762
Total current assets	9,597	9,260
Property, plant and equipment, net	7,518	6,098
Other assets
Goodwill	3,780	2,502
Other intangible assets, net	2,682	814
Other	1,673	1,716
Total other assets	8,135	5,032
Total assets	25,250	20,390
Current liabilities
Short-term debt	42	27
Current maturities of long-term debt and lease obligations	372	323
Accounts payable and accrued liabilities	4,582	4,409
Total current liabilities	4,996	4,759
Long-term debt and lease obligations	8,652	5,580
Other long-term liabilities	3,856	3,073
Commitments and contingencies
Equity
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2013 and 2012	683	683
Common stock in treasury, at cost, 140,445,862 shares in 2013 and 137,281,399 shares in 2012	-7,911	-7,592
Additional contributed capital	5,785	5,769
Retained earnings	11,792	10,888
Accumulated other comprehensive loss	-2,600	-2,810
Total Baxter shareholders' equity	7,749	6,938
Noncontrolling interests	-3	40
Total equity	7,746	6,978
Total liabilities and equity	$25,250	$20,390

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Common stock, par value	$1	$1
Common stock, authorized	2,000,000,000	2,000,000,000
Common stock, issued	683,494,944	683,494,944
Treasury stock, shares	140,445,862	137,281,399

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operations
Net income	$1,686	$1,832
Adjustments
Depreciation and amortization	573	534
Deferred income taxes	85	197
Stock compensation	111	97
Realized excess tax benefits from stock issued under employee benefit plans	-32	-14
Other	2	-47
Changes in balance sheet items
Accounts and other current receivables, net	70	72
Inventories	-412	-136
Accounts payable and accrued liabilities	-56	-282
Business optimization and infusion pump payments	-81	-226
Other	169	134
Cash flows from operations	2,115	2,161
Cash flows from investing activities
Capital expenditures	-1,037	-762
Acquisitions and investments	-3,772	-495
Other investing activities	14	86
Cash flows from investing activities	-4,795	-1,171
Cash flows from financing activities
Issuances of debt, net of issuance costs	3,498	1,022
Payments of obligations	-526	-18
Decrease in debt with original maturities of three months or less, net		-250
Cash dividends on common stock	-757	-558
Proceeds and realized excess tax benefits from stock issued under employee benefit plans	468	307
Purchases of treasury stock	-863	-1,065
Other	-25	-102
Cash flows from financing activities	1,795	-664
Effect of currency exchange rate changes on cash and equivalents	-9	-40
(Decrease) increase in cash and equivalents	-894	286
Cash and equivalents at beginning of period	3,270	2,905
Cash and equivalents at end of period	$2,376	$3,191

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Basis of Presentation	1. BASIS OF PRESENTATION
	The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (the company or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2012 (2012 Annual Report).
	On September 6, 2013, Baxter completed the acquisition of Gambro AB (Gambro) for cash consideration of $3.7 billion, as reduced by $221 million of assumed debt. Beginning September 6, 2013, Baxter’s financial statements include the assets, liabilities and operating results of Gambro. Refer to Note 4 for additional information.
	In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the interim periods. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The results of operations for the interim period are not necessarily indicative of the results of operations to be expected for the full year.
	Changes in accounting standards
	Effective January 1, 2013, the company prospectively adopted new accounting guidance that requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in the condensed consolidated statement of income. Refer to Note 2 for related disclosures.

Supplemental_Financial_Informa

Supplemental Financial Information	9 Months Ended
	Sep. 30, 2013
Supplemental Financial Information	2. SUPPLEMENTAL FINANCIAL INFORMATION
	Net interest expense
			Three months ended						Nine months ended
			September 30,						September 30,
	(in millions)		2013			2012			2013			2012
	Interest expense, net of capitalized interest			$51			$31			$106			$85
	Interest income			(6	)		(6	)		(19	)		(20	)
	Net interest expense			$45			$25			$  87			$65
	Inventories
	(in millions)		September 30,			December 31,
			2013			2012
	Raw materials			$   967			$   765
	Work in process			1,009			898
	Finished goods			1,605			1,140
	Inventories			$3,581			$2,803
	Property, plant and equipment, net
	(in millions)		September 30,			December 31,
			2013			2012
	Property, plant and equipment, at cost			$13,324			$11,869
	Accumulated depreciation and amortization			(5,806	)		(5,771	)
	Property, plant and equipment (PP&E), net			$  7,518			$  6,098
	Accumulated other comprehensive income (AOCI)
	Comprehensive income includes all changes in shareholders’ equity that do not arise from transactions with shareholders, and consists of net income, currency translation adjustments (CTA), pension and other employee benefits, unrealized gains and losses on cash flow hedges and unrealized gains and losses on unrestricted available-for-sale marketable equity securities. The following is a net-of-tax summary of the changes in AOCI by component for the nine months ended September 30, 2013.
	(in millions)		Currency			Pension and			Hedging			Other			Total
			translation			other employee			activities
			adjustments			benefits
	Gains (losses)
	Balance as of December 31, 2012			($1,227	)		($1,619	)		($  5	)		$41			($2,810	)
	Other comprehensive income before reclassifications			58			(5	)		44			12			109
	Amounts reclassified from AOCI (a)			—			124			(23	)		—			101
	Net other comprehensive income			58			119			21			12			210
	Balance as of September 30, 2013			($1,169	)		($1,500	)		$16			$53			($2,600	)
	(a)	See table below for details about the reclassifications for the nine months ended September 30, 2013.
	The following is a summary of the amounts reclassified from AOCI to net income during the three and nine months ended September 30, 2013.
			Amounts reclassified from AOCI (a)
	(in millions)		Three months ended			Nine months ended			Location of impact in income statement
			September 30, 2013			September 30, 2013
	Amortization of pension and other employee benefits items
	Actuarial losses and other			($64	) (b)		($191	) (b)
				(64	)		(191	)	Total before tax
				23			67		Tax benefit
				($41	)		($124	)	Net of tax
	Gains (losses) on hedging activities
	Interest rate contracts			$ (1	)		$  10		Net interest expense
	Foreign exchange contracts			—			(1	)	Net sales
	Foreign exchange contracts			9			27		Cost of sales
				8			36		Total before tax
				(3	)		(13	)	Tax expense
				$  5			$  23		Net of tax
	Total reclassification for the period			($36	)		($101	)	Total net of tax
	(a)	Amounts in parentheses indicate reductions to net income.
	(b)	These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 9.
	Refer to Note 9 for additional information regarding the amortization of pension and other employee benefits items and Note 7 for additional information regarding hedging activity.
	Asset impairments
	Baxter has made and continues to make significant investments in assets, including inventory and PP&E, which relate to potential new products or modifications to existing products. Additionally, Baxter has made and continues to make significant investments related to business development activities, which result in the acquisition of certain intangible assets and other long-lived assets. The company’s ability to realize value from these investments is contingent on, among other things, regulatory approvals, technical success, market acceptance of new or modified products, and realization of synergies associated with business acquisitions. The company may not be able to realize the expected returns from these investments, potentially resulting in asset impairments in the future.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share	3. EARNINGS PER SHARE
	The numerator for both basic and diluted earnings per share (EPS) is net income. The denominator for basic EPS is the weighted-average number of common shares outstanding during the period. The dilutive effect of outstanding stock options, restricted stock units (RSUs) and performance share units (PSUs) is reflected in the denominator for diluted EPS using the treasury stock method.
	The following is a reconciliation of basic shares to diluted shares.
		Three months ended				Nine months ended
		September 30,				September 30,
	(in millions)	2013		2012		2013		2012
	Basic shares		543		548		543		552
	Effect of dilutive securities		6		4		7		4
	Diluted shares		549		552		550		556
	The effect of dilutive securities included unexercised stock options, unvested RSUs and contingently issuable shares related to granted, unvested PSUs. The computation of diluted EPS excluded stock options to purchase 6 million and 17 million shares for the third quarters of 2013 and 2012, respectively, and 5 million and 22 million shares for the nine months ended September 30, 2013 and 2012, respectively, because their inclusion would have had an anti-dilutive effect on diluted EPS.

Acquisitions_and_Collaboration

Acquisitions and Collaborations	9 Months Ended
	Sep. 30, 2013
Acquisitions and Collaborations	4. ACQUISITIONS AND COLLABORATIONS
	Gambro AB Acquisition
	Description of transaction
	On September 6, 2013, Baxter acquired 100 percent of the voting equity interests in Indap Holding AB, the holding company for Gambro AB (Gambro), a privately held dialysis product company based in Lund, Sweden. Gambro is a global medical technology company focused on developing, manufacturing and supplying dialysis products and therapies for patients with acute or chronic kidney disease. The transaction provides Baxter with a broad and complementary dialysis product portfolio, while further advancing the company’s geographic footprint in the dialysis business. In addition, the company has augmented its pipeline with Gambro’s next-generation monitors, dialyzers, devices and dialysis solutions.
	Fair value of consideration transferred and net assets acquired
	Baxter provided total cash consideration of $3.7 billion for the acquisition, as reduced by assumed debt of $221 million. The valuation of assets acquired and liabilities assumed in the transaction has not yet been completed as of September 30, 2013. As a result, Baxter has recorded preliminary estimates for the fair value of assets acquired and liabilities assumed as of the acquisition date. The completion of the valuation will occur no later than one year from the acquisition date and may result in significant changes to the recognized assets and liabilities.
	The following table summarizes the fair value of the consideration transferred and the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date.
	(in millions)
	Consideration transferred
	Cash		$	3,704
	Fair value of consideration transferred		$	3,704
	Assets acquired and liabilities assumed
	Cash		$	88
	Accounts receivable			483
	Inventories			367
	Prepaid expenses and other			54
	Property, plant, and equipment			854
	Other intangible assets			1,650
	Other assets			11
	Current-maturities of long-term debt and lease obligations			(2	)
	Accounts payable and accrued liabilities			(334	)
	Long-term debt and lease obligations			(261	)
	Other long-term liabilities (including pension obligations of $214)			(458	)
	Total identifiable net assets			2,452
	Goodwill			1,252
	Total assets acquired and liabilities assumed		$	3,704
	The results of operations, assets and liabilities of Gambro are included in the Medical Products segment, and the goodwill is also included in this reporting unit. Goodwill includes expected synergies, as well as an expanded dialysis product portfolio and global footprint for the company’s Medical Products business, particularly the Renal franchise. The goodwill is not deductible for tax purposes. Other intangible assets primarily relate to developed technology and are currently being amortized on a straight-line basis over an estimated average useful life of 12.5 years.
	Long-term debt and lease obligations included $221 million of Gambro’s pre-existing Euro-denominated debt assumed by Baxter on the date of closing, which was subsequently paid off in September 2013. The debt settlement has been classified as a financing activity in the consolidated statement of cash flows.
	Acquisition-related costs
	The company incurred acquisition-related costs of $18 million and $58 million during the third quarter and first nine months of 2013, respectively, which were recorded in marketing and administrative expenses.
	Actual and pro forma impact of acquisition
	The following table presents information for Gambro that is included in Baxter’s consolidated statement of income from the acquisition date through September 30, 2013.
	(in millions)		Gambro’s operations
			included in Baxter’s
			results
	Net sales			$100
	Net loss			$ (17	)
	Net loss related to Gambro includes purchase accounting impacts related to fair value adjustments associated with acquisition-date inventory that was sold during the third quarter of 2013 (approximately $15 million on a pre-tax basis).
	The following table presents supplemental pro forma information as if the acquisition of Gambro had occurred on January 1, 2012 for the three and nine months ended September 30, 2013 and 2012.
			Unaudited Pro Forma Consolidated Results
			Three months ended					Nine months ended
			September 30,					September 30,
	(in millions, except per share information)		2013			2012		2013		2012
	Net sales		$	4,038		$	3,855	$	11,933	$	11,594
	Net income			547			568		1,713		1,613
	Basic earnings per share		$	1.01		$	1.04	$	3.16	$	2.92
	Diluted earnings per share		$	1		$	1.03	$	3.11	$	2.9
	The unaudited pro forma consolidated results were prepared using the acquisition method of accounting and are based on the historical information of Baxter and Gambro. The unaudited pro forma consolidated results are not necessarily indicative of what the consolidated results of operations would have been had we completed the acquisition on January 1, 2012. In addition, the unaudited pro forma consolidated results are not projections of future results of operations of the combined company nor do they reflect the expected realization of any cost savings or synergies associated with the acquisition. The unaudited pro forma consolidated results reflect primarily the following pro forma pre-tax adjustments:
		•		Conversion of Gambro’s historical results of operations from International Financial Reporting Standards (IFRS) to GAAP.
		•		Elimination of Gambro’s historical intangible asset amortization expense and property, plant and equipment depreciation expense.
		•		Addition of amortization expense related to the fair value of identifiable intangible assets acquired.
		•		Addition of depreciation expense related to the fair value of property, plant and equipment acquired.
		•		Elimination of a $15 million charge related to the fair value of acquisition-date inventory from the three- and nine-month periods ended September 30, 2013.
		•		Addition of a $60 million charge related to the fair value of acquisition-date inventory to the nine-month period ended September 30, 2012.
		•		Elimination of Gambro’s historical interest expense and addition of interest expense associated with debt that was issued in 2013 to partially finance the acquisition.
		•		Elimination of $135 million of acquisition, integration and currency-related charges from the first nine months of 2013 and addition of these costs to the first nine months of 2012. These costs were directly attributable to the acquisition and non-recurring in nature, and included acquisition and integration related charges incurred by Baxter, in addition to post-acquisition restructuring costs and losses from foreign currency hedging activity related to the acquisition.
	Other Acquisitions
	Inspiration / Ipsen OBI-1 business
	In March 2013, Baxter acquired the investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals, Inc. (Inspiration), as well as certain other OBI-1 related assets, including manufacturing operations, from Ipsen Pharma S.A.S. (Ipsen) in conjunction with Inspiration’s bankruptcy proceedings. OBI-1 is a recombinant porcine factor VIII (rpFVIII) being investigated for treatment of bleeding in people with acquired hemophilia A and congenital hemophilia A patients with inhibitors. Ipsen was Inspiration’s senior secured creditor and had been providing Inspiration with debtor-in-possession financing to fund Inspiration’s operations and the sales process. Additionally, Ipsen was the owner of certain assets acquired by Baxter in the transaction.
	The acquired net assets comprised a business based on the acquired inputs, processes and outputs and, as a result, the transaction has been accounted for as an acquisition of a business. In March 2013, Baxter made an upfront payment of $51 million for the Inspiration / Ipsen OBI-1 business. The terms of the acquisition also included contingent consideration, including up to $135 million in payments related to the achievement of certain regulatory and sales milestones. Additionally, Baxter will be responsible for specified sales-based payments.
	The company substantially completed its valuation of consideration transferred and intangible assets during the second quarter of 2013. As a result, Baxter adjusted its preliminary estimates of the fair value of consideration transferred and assets acquired and liabilities assumed as of the acquisition date. The measurement period adjustments resulted in a reduction to consideration transferred of $58 million, and reductions of $55 million and $3 million to other intangible assets and goodwill, respectively. In the third quarter of 2013, the company recorded an additional measurement period adjustment to increase consideration transferred by $2 million with a corresponding increase in goodwill.
	The following table summarizes the updated estimated fair value of consideration transferred and the recognized amounts of the assets acquired and liabilities assumed as of the acquisition date for the Inspiration / Ipsen OBI-1 business.
	(in millions)
	Consideration transferred
Cash			$  51
Contingent payments			269
Fair value of consideration transferred			$320
Assets acquired and liabilities assumed
Other intangible assets			$288
Other assets, net			25
Goodwill			7
Total assets acquired and liabilities assumed			$320
The estimated fair value of contingent payment liabilities at the acquisition date was $269 million, based on the probability of achieving the specified milestones and sales-based payments and the discounting of expected future cash flows, and was recorded in other long-term liabilities as part of the consideration transferred. The fair value of the contingent payment liabilities will be re-measured in future periods with changes in the estimated fair value recognized in earnings.
Goodwill of $7 million principally includes the value associated with the assembled workforce at the acquired manufacturing facility. The goodwill is deductible for tax purposes. Other intangible assets of $288 million related to acquired in-process research and development (IPR&D) activities associated with OBI-1 and were accounted for as an indefinite-lived intangible asset. If regulatory approvals are obtained, the IPR&D assets will be amortized over the estimated economic life of the product, and the amortization expense will be recorded in cost of sales.
The results of operations, assets and liabilities of the Inspiration / Ipsen OBI-1 business are included in the BioScience segment, and the goodwill is also included in this reporting unit. Pro forma financial information has not been presented because the results of the acquired business are not material to the company’s results of operations.
Collaborations
Coherus Biosciences, Inc.
In August 2013, Baxter and Coherus Biosciences, Inc. (Coherus) entered into an exclusive collaboration to develop and commercialize a biosimilar to etanercept for Europe, Canada, Brazil and certain other markets. Baxter also has specified rights to include additional products in the collaboration. Baxter’s upfront payment of $30 million was recorded as a deposit asset, with disposition dependent on future Baxter decisions. Development and manufacturing activities will principally be conducted by Coherus, and Baxter will perform the commercialization function. Baxter may make additional payments of up to $216 million relating to the achievement of development and regulatory milestones, as well as royalties based on net sales.
JW Holdings Corporation
In July 2013, Baxter and JW Holdings Corporation (JW Holdings) entered into an exclusive collaboration agreement for parenteral nutritional products containing a novel formulation of omega 3 lipids. Baxter has exclusive rights to co-develop and distribute the products globally, with the exception of Korea. In the third quarter of 2013, Baxter recognized an R&D charge of $25 million related to an upfront cash payment associated with the execution of the agreement. Baxter may make additional payments of up to $10 million relating to the achievement of regulatory milestones, in addition to future royalties.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets, Net	9 Months Ended
	Sep. 30, 2013
Goodwill and Other Intangible Assets, Net	5. GOODWILL AND OTHER INTANGIBLE ASSETS, NET
	Impairment tests for goodwill and intangible assets not subject to amortization are performed annually in the fourth quarter, or sooner if indicators of impairment exist. Intangible assets subject to amortization are tested for impairment when indicators of impairment exist.
	Goodwill
	The following is a reconciliation of goodwill by business segment.
	(in millions)	BioScience			Medical			Total
					Products
	Balance as of December 31, 2012		$975			$1,527			$2,502
	Additions		7			1,254			1,261
	Currency translation and other adjustments		4			13			17
	Balance as of September 30, 2013		$986			$2,794			$3,780
	Goodwill additions principally related to the third quarter 2013 acquisition of Gambro and the first quarter 2013 acquisition of the Inspiration / Ipsen OBI-1 business. Refer to Note 4 for additional information regarding these acquisitions. As of September 30, 2013, there were no accumulated goodwill impairment losses.
	Other intangible assets, net
	Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets not subject to amortization include a trademark with an indefinite life and acquired IPR&D associated with products that have not yet received regulatory approval.
	The following is a summary of the company’s other intangible assets.
	(in millions)	Developed technology,			Other amortized			Indefinite-lived		Total
		including patents			intangible assets			intangible  assets
	September 30, 2013
	Gross other intangible assets		$2,850			$281			$309		$3,440
	Accumulated amortization		(630	)		(128	)		—		(758	)
	Other intangible assets, net		$2,220			$153			$309		$2,682
	December 31, 2012
	Gross other intangible assets		$1,192			$280			$  22		$1,494
	Accumulated amortization		(578	)		(102	)		—		(680	)
	Other intangible assets, net		$   614			$178			$  22		$   814
	The intangible asset amortization expense was $34 million and $26 million in the three months ended September 30, 2013 and 2012, respectively, and $84 million and $76 million in the nine months ended September 30, 2013 and 2012, respectively. The anticipated annual amortization expense for intangible assets currently subject to amortization as of September 30, 2013 is $142 million in 2013, $227 million in 2014, $225 million in 2015, $222 million in 2016, $204 million in 2017 and $199 million in 2018.
	The increase in developed technology intangible assets during 2013 was primarily driven by the acquisition of Gambro in the third quarter of 2013. The increase in indefinite-lived intangible assets during 2013 was primarily related to the acquisition of the Inspiration / Ipsen OBI-1 business in the first quarter of 2013. Refer to Note 4 for additional information regarding these acquisitions.

Infusion_Pump_and_Business_Opt

Infusion Pump and Business Optimization Charges	9 Months Ended
	Sep. 30, 2013
Infusion Pump and Business Optimization Charges	6. INFUSION PUMP AND BUSINESS OPTIMIZATION CHARGES
	Infusion pump charges
	From 2005 through 2012, the company recorded total charges and adjustments of $888 million related to COLLEAGUE and SYNDEO infusion pumps, including $742 million of cash costs and $146 million principally related to asset impairments. The company had $127 million of the cash reserves remaining as of December 31, 2012. Refer to Note 6 to the company’s consolidated financial statements in the 2012 Annual Report for further information about the COLLEAGUE and SYNDEO charges and adjustments.
	The following table summarizes cash activity in the company’s COLLEAGUE infusion pump reserves through September 30, 2013.
	(in millions)
	Reserves as of December 31, 2012	$127
	Utilization	(20	)
	Reserves as of September 30, 2013	$107
	The reserve for remediation activities in the United States has been substantially utilized, with remaining reserves primarily related to remediation activities outside of the United States continuing to be utilized through 2014. In January 2013, Baxter received license approvals in Canada for a replacement infusion pump that will allow the company to complete remediation activities in Canada. The company believes that the remaining infusion pump reserves are adequate. However, additional adjustments may be recorded in the future as the programs are completed.
	It is possible that substantial additional cash and non-cash charges may be required in future periods based on new information, changes in estimates, and actions the company may be required to undertake in markets outside the United States.
	Business optimization charges
	From 2009 through 2012 the company recorded total charges of $678 million primarily related to costs associated with optimizing the company’s overall cost structure on a global basis, as the company streamlined its international operations, rationalized its manufacturing facilities, enhanced its general and administrative infrastructure and, in 2012, re-aligned certain R&D activities. The total charges included cash costs of $507 million, principally pertaining to severance and other employee-related costs, and $171 million related to asset impairments. The company had $220 million of the cash reserves remaining as of December 31, 2012. Refer to the 2012 Annual Report for further information about these charges.
	In the third quarter of 2013, in connection with the Gambro acquisition, the company recorded a charge of $14 million related to post-acquisition restructuring activities.
	In the second quarter of 2013, the company recorded a charge of $18 million related to contract termination and other exit costs associated with the discontinuation of the company’s Alzheimer’s program. Additionally, in the second quarter of 2013, the company recorded adjustments of $20 million to previous business optimization reserves that are no longer probable of being utilized.
	The following table summarizes cash activity in the reserves related to the company’s business optimization initiatives.
	(in millions)
	Reserves as of December 31, 2012	$220
	Charges	32
	Reserve adjustments	(20	)
	Utilization	(61	)
	CTA	3
	Reserves as of September 30, 2013	$174
	The reserves are expected to be substantially utilized by the end of 2014. The company believes that these reserves are adequate. However, adjustments may be recorded in the future as the programs are completed.

Debt_Financial_Instruments_and

Debt, Financial Instruments and Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Debt, Financial Instruments and Fair Value Measurements	7. DEBT, FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
	Securitization arrangement
	The following is a summary of the activity relating to the company’s securitization arrangement in Japan.
		Three months ended							Nine months ended
		September 30,							September 30,
	(in millions)	2013				2012			2013				2012
	Sold receivables at beginning of period		$  129				$  154			$  157				$  160
	Proceeds from sales of receivables		125				161			380				461
	Cash collections (remitted to the owners of the receivables)		(130	)			(161	)		(394	)			(465	)
	Effect of currency exchange rate changes		(6	)			—			(25	)			(2	)
	Sold receivables at end of period		$  118				$  154			$  118				$  154
	The net losses relating to the sales of receivables were immaterial for each period. Refer to the 2012 Annual Report for further information regarding the company’s securitization agreements.
	Significant debt issuances
	In June 2013, the company issued $500 million of floating rate senior notes maturing in December 2014, $500 million of senior notes bearing a coupon rate of 0.95% and maturing in June 2016, $750 million of senior notes bearing a coupon rate of 1.85% and maturing in June 2018, $1.25 billion of senior notes bearing a coupon rate of 3.2% and maturing in June 2023, and $500 million of senior notes bearing a coupon rate of 4.5% and maturing in June 2043. The interest rate on the floating rate senior notes was 0.4259% as of September 30, 2013.
	Approximately $3.0 billion of the net proceeds of these debt issuances was used to finance the acquisition of Gambro and the remainder has been and will be used for general corporate purposes, including the repayment of commercial paper.
	Credit facilities and commercial paper
	As of September 30, 2013 and December 31, 2012, there were no outstanding borrowings under the company’s primary and Euro-denominated revolving credit facilities. In October 2013, the company’s Euro-denominated credit revolving facility, which was set to mature in October 2013, was amended and extended to December 2014. The terms of the new Euro-denominated revolving credit facility did not substantially change, however certain provisions were amended to more closely align with the company’s primary credit facility. Refer to Note 7 to the company’s consolidated financial statements in the 2012 Annual Report for further discussion of the company’s credit facilities.
	During the first nine months of 2013, the company issued and redeemed commercial paper, and there was no balance outstanding as of both September 30, 2013 and December 31, 2012.
	In January 2013, Baxter entered into an agreement related to a 364-day bridge loan facility with a maximum capacity of $3.1 billion in support of the planned acquisition of Gambro. This facility was terminated in the second quarter of 2013 as a result of the company’s June 2013 issuance of debt. The company recognized a $13 million expense related to bridge loan facility structuring and commitment fees in other (income) expense, net during the second quarter of 2013.
	Concentrations of credit risk
	The company invests excess cash in certificates of deposit or money market funds and diversifies the concentration of cash among different financial institutions. With respect to financial instruments, where appropriate, the company has diversified its selection of counterparties, and has arranged collateralization and master-netting agreements to minimize the risk of loss.
	The company continues to do business with foreign governments in certain countries, including Greece, Spain, Portugal and Italy, that have experienced a deterioration in credit and economic conditions. As of September 30, 2013, the company’s net accounts receivable from the public sector in Greece, Spain, Portugal and Italy totaled $559 million (of which $43 million related to Greece) and includes $141 million of Gambro-related receivables.
	Global economic conditions and liquidity issues in certain countries have resulted, and may continue to result, in delays in the collection of receivables and credit losses. Governmental actions and customer-specific factors may also require the company to re-evaluate the collectibility of its receivables and the company could potentially incur additional credit losses. These conditions may also impact the stability of the Euro.
	Derivatives and hedging activities
	The company operates on a global basis and is exposed to the risk that its earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. The company’s hedging policy attempts to manage these risks to an acceptable level based on the company’s judgment of the appropriate trade-off between risk, opportunity and costs.
	The company is primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, Japanese Yen, British Pound, Australian Dollar, Canadian Dollar, Brazilian Real, Colombian Peso, and Swedish Krona. The company manages its foreign currency exposures on a consolidated basis, which allows the company to net exposures and take advantage of any natural offsets. In addition, the company uses derivative and nonderivative instruments to further reduce the net exposure to foreign exchange. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from foreign exchange. Financial market and currency volatility may limit the company’s ability to cost-effectively hedge these exposures.
	The company is also exposed to the risk that its earnings and cash flows could be adversely impacted by fluctuations in interest rates. The company’s policy is to manage interest costs using a mix of fixed- and floating-rate debt that the company believes is appropriate. To manage this mix in a cost-efficient manner, the company periodically enters into interest rate swaps in which the company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount.
	The company does not hold any instruments for trading purposes and none of the company’s outstanding derivative instruments contain credit-risk-related contingent features.
	All derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. Based upon the exposure being hedged, the company designates its hedging instruments as cash flow or fair value hedges.
	Cash Flow Hedges
	The company may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. The company periodically uses forward-starting interest rate swaps and treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt. Certain other firm commitments and forecasted transactions are also periodically hedged.
	For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is accumulated in AOCI and then recognized in earnings consistent with the underlying hedged item. Option premiums or net premiums paid are initially recorded as assets and reclassified to other comprehensive income (OCI) over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in net sales, cost of sales, and net interest expense, and primarily relate to forecasted third-party sales denominated in foreign currencies, forecasted intercompany sales denominated in foreign currencies, and anticipated issuances of debt, respectively.
	The notional amounts of foreign exchange contracts were $2.2 billion and $1.5 billion as of September 30, 2013 and December 31, 2012, respectively. The notional amount of interest rate contracts designated as cash flow hedges outstanding as of December 31, 2012 was $250 million. There were no interest rate contracts designated as cash flow hedges outstanding as of September 30, 2013. The maximum term over which the company has cash flow hedge contracts in place related to forecasted transactions as of September 30, 2013 is 15 months.
	Fair Value Hedges
	The company uses interest rate swaps to convert a portion of its fixed-rate debt into variable-rate debt. These instruments hedge the company’s earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. Fair value hedges are classified in net interest expense, as they hedge the interest rate risk associated with certain of the company’s fixed-rate debt.
	The total notional amount of interest rate contracts designated as fair value hedges was $500 million as of both September 30, 2013 and December 31, 2012.
	Dedesignations
	If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, the company discontinues hedge accounting prospectively. If the company removes the cash flow hedge designation because the hedged forecasted transactions are no longer probable of occurring, any gains or losses are immediately reclassified from AOCI to earnings. Gains or losses relating to terminations of effective cash flow hedges in which the forecasted transactions are still probable of occurring are deferred and recognized consistent with the loss or income recognition of the underlying hedged items.
	In the first nine months of 2013, the company had $1 billion of interest rate contracts designated as cash flow hedges that matured or were terminated, resulting in a net gain of $5 million that was deferred in AOCI. In the second quarter of 2013, the company determined that certain forecasted transactions associated with these contracts were no longer probable of occurring and therefore dedesignated the hedge relationship, which, together with ineffectiveness, resulted in the immediate reclassification of a net gain of $11 million from AOCI to net interest expense. The remaining deferred net loss of $6 million from the matured or terminated interest rate contracts is amortized to net interest expense against the related accrued interest payments. There were no hedge dedesignations in the first nine months of 2012 resulting from changes in the company’s assessment of the probability that the hedged forecasted transactions would occur.
	If the company terminates a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged items at the date of termination is amortized to earnings over the remaining term of the hedged item. In the first nine months of 2012, the company terminated $175 million of interest rate contracts that had been designated as fair value hedges, which resulted in a net gain of $21 million that was deferred and is being amortized as a reduction of net interest expense over the remaining term of the underlying debt. There were no fair value hedges terminated during the first nine months of 2013.
	Undesignated Derivative Instruments
	The company uses forward contracts to hedge earnings from the effects of foreign exchange relating to certain of the company’s intercompany and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges, and the change in fair value, which substantially offsets the change in book value of the hedged items, is recorded directly to other (income) expense, net. The terms of these instruments generally do not exceed one month.
	The total notional amount of undesignated derivative instruments was $318 million as of September 30, 2013 and $3.2 billion as of December 31, 2012. In the fourth quarter of 2012 and the first quarter of 2013, the company entered into option contracts with a total notional amount of $3.7 billion to hedge anticipated foreign currency cash outflows associated with the acquisition of Gambro. These contracts matured in June 2013, and in the second quarter of 2013, the company entered into undesignated forward contracts with a total notional amount of $1.5 billion also to hedge anticipated foreign currency cash outflows associated with the acquisition of Gambro, which matured in the third quarter of 2013. The company recorded gains of $49 million and losses of $23 million in the three and nine months ended September 30, 2013, respectively, associated with the Gambro-related option and forward contracts.
	Gains and Losses on Derivative Instruments
	The following table summarizes the income statement locations and gains and losses on the company’s derivative instruments for the three months ended September 30, 2013 and 2012.
		Gain (loss) recognized in OCI							Location of gain (loss) in		Gain (loss) reclassified from AOCI
									income statement		into income
	(in millions)	2013				2012					2013				2012
	Cash flow hedges
	Interest rate contracts		$—				$  (3	)	Net interest expense			$  (1	)			$—
	Foreign exchange contracts		(1	)			(1	)	Net sales			—				(1	)
	Foreign exchange contracts		7				(20	)	Cost of sales			9				5
	Total		$  6				$(24	)				$   8				$  4
											Gain (loss) recognized in income
	(in millions)								Location of gain (loss) in		2013				2012
									income statement
	Fair value hedges
	Interest rate contracts								Net interest expense			$  1				$  5
	Undesignated derivative instruments
	Foreign exchange contracts								Other (income) expense, net			$51				$ (2	)
	The following table summarizes the income statement locations and gains and losses on the company’s derivative instruments for the nine months ended September 30, 2013 and 2012.
		Gain (loss) recognized in OCI							Location of gain (loss) in		Gain (loss) reclassified from
									income statement		AOCI into income
	(in millions)	2013				2012					2013				2012
Cash flow hedges
Interest rate contracts		$26				$(12	)	Net interest expense			$10				$ —
Foreign exchange contracts		(1	)			(2	)	Net sales			(1	)			(2	)
Foreign exchange contracts		43				(11	)	Cost of sales			27				4
Total		$68				$(25	)				$36				$   2
										Gain (loss) recognized in income
(in millions)								Location of gain (loss) in		2013				2012
								income statement
Fair value hedges
Interest rate contracts								Net interest expense			$(25	)			$ 15
Undesignated derivative instruments
Foreign exchange contracts								Other (income) expense, net			$   6				$(13	)
For the company’s fair value hedges, equal and offsetting losses of $1 million and gains of $25 million were recognized in net interest expense in the third quarter and first nine months of 2013, respectively, and equal and offsetting losses of $5 million and $15 million were recognized in net interest expense in the third quarter and first nine months of 2012, respectively, as adjustments to the underlying hedged item, fixed-rate debt. Ineffectiveness related to the company’s cash flow and fair value hedges for the nine months ended September 30, 2013 was not material.
As of September 30, 2013, $9 million of deferred, net after-tax gains on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings.
Fair Values of Derivative Instruments
The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of September 30, 2013.
	Derivatives in asset positions						Derivatives in liability positions
(in millions)	Balance sheet location		Fair value				Balance sheet location	Fair value
Derivative instruments designated as hedges
Interest rate contracts	Other long-term assets			$  42			Other long-term liabilities		$—
Foreign exchange contracts	Prepaid expenses and other			46			Accounts payable		6
							and accrued liabilities
Foreign exchange contracts	Other long-term assets			8			Other long-term liabilities		1
Total derivative instruments designated as hedges				$  96					$  7
Undesignated derivative instruments
Foreign exchange contracts	Prepaid expenses and other			$  —			Accounts payable		$  1
							and accrued liabilities
Total derivative instruments				$  96					$  8
The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2012.
	Derivatives in asset positions						Derivatives in liability positions
(in millions)	Balance sheet location		Fair value				Balance sheet location	Fair value
Derivative instruments designated as hedges
Interest rate contracts	Other long-term assets			$  67			Accounts payable		$21
							and accrued liabilities
Foreign exchange contracts	Prepaid expenses and other			28			Accounts payable		5
							and accrued liabilities
Total derivative instruments designated as hedges				$  95					$26
Undesignated derivative instruments
Foreign exchange contracts	Prepaid expenses and other			$  47			Accounts payable		$11
							and accrued liabilities
Total derivative instruments				$142					$37
While the company’s derivatives are all subject to master netting arrangements, the company presents its assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, the company is not required to post collateral for any of its outstanding derivatives.
The following table provides information on the company’s derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.
	September 30, 2013							December 31, 2012
(in millions)	Asset				Liability			Asset				Liability
Gross amounts recognized in the consolidated balance sheet		$96				$  8			$142				$37
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet		(8	)			(8	)		(37	)			(37	)
Total		$88				$—			$105				$—
Fair value measurements
The following tables summarize the bases used to measure financial assets and liabilities that are carried at fair value on a recurring basis in the condensed consolidated balance sheets.
					Basis of fair value measurement
(in millions)	Balance as of				Quoted prices in			Significant other				Significant
	September 30, 2013				active markets for			observable inputs				unobservable
					identical assets			(Level 2)				inputs
					(Level 1)							(Level 3)
Assets
Foreign currency hedges		$  54				$  —			$  54				$  —
Interest rate hedges		42				—			42				—
Available-for-sale securities
Equity securities		110				110			—				—
Foreign government debt securities		17				—			17				—
Total assets		$223				$110			$113				$  —
Liabilities
Foreign currency hedges		$    8				$  —			$    8				$  —
Contingent payments related to acquisitions		344				—			—				344
Total liabilities		$352				$  —			$    8				$344
					Basis of fair value measurement
(in millions)	Balance as of				Quoted prices in			Significant other				Significant
	December 31, 2012				active markets for			observable inputs				unobservable
					identical assets			(Level 2)				inputs
					(Level 1)							(Level 3)
Assets
Foreign currency hedges		$  75				$—			$  75				$—
Interest rate hedges		67				—			67				—
Available-for-sale securities
Equity securities		15				15			—				—
Preferred stock		51				—			—				51
Foreign government debt securities		16				—			16				—
Total assets		$224				$15			$158				$51
Liabilities
Foreign currency hedges		$  16				$—			$  16				$—
Interest rate hedges		21				—			21				—
Contingent payments related to acquisitions		86				—			—				86
Total liabilities		$123				$—			$  37				$86
As of September 30, 2013, cash and equivalents of $2.4 billion included money market funds of approximately $1.1 billion, which would be considered Level 2 in the fair value hierarchy.
For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The majority of the derivatives entered into by the company are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs are considered observable and vary depending on the type of derivative, and include contractual terms, interest rate yield curves, foreign exchange rates and volatility. The fair values of foreign government debt securities are obtained from pricing services or broker/dealers who use proprietary pricing applications, which include observable market information for like or same securities. The preferred stock was valued based upon recent transactions, as well as the financial information of the investee.
Contingent payments related to acquisitions consist of development and commercial milestone payments, in addition to sales-based payments, and are valued using discounted cash flow techniques. The fair value of development and commercial milestone payments reflects management’s expectations of probability of payment, and increases as the probability of payment increases or expectation of timing of payments is accelerated. As of September 30, 2013, management’s expected weighted-average probability of payment for development and commercial milestone payments was approximately 55%. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increase or expectation of timing of payment is accelerated.
At September 30, 2013, the company held available-for-sale equity securities that had an amortized cost basis and fair value of $91 million and $110 million, respectively, with $19 million of cumulative net unrealized gains. At December 31, 2012, the amortized cost basis and fair value of the available-for-sale equity securities was $13 million and $15 million, respectively, with $2 million in cumulative unrealized gains.
As of September 30, 2013 and December 31, 2012, the cumulative unrealized gains for the company’s available-for-sale debt securities were less than $1 million. The company recognized losses totaling $8 million in 2012 related to unrealized and realized losses associated with the company’s Greek government and European Financial Stability Facility bonds, which Baxter sold in the second quarter of 2012. Refer to the 2012 Annual Report for more information on the company’s Greek debt holdings.
The following table is a reconciliation of the fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions and preferred stock.
(in millions)	Contingent				Preferred
	payments				stock
Fair value as of December 31, 2012		$  86				$51
Additions		269				—
Payments		(2	)			—
Gains recognized in earnings		(9	)			—
Conversion to a publicly traded equity security		—				(51	)
Fair value as of September 30, 2013		$344				$—
Additions were related to contingent payment liabilities associated with the acquisition of the Inspiration / Ipsen OBI-1 business in the first quarter of 2013, and were updated to reflect the measurement period adjustments recorded in the second and third quarters of 2013, as discussed in Note 4.
Book Values and Fair Values of Financial Instruments
In addition to the financial instruments that the company is required to recognize at fair value in the condensed consolidated balance sheets, the company has certain financial instruments that are recognized at historical cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the approximate fair values as of September 30, 2013 and December 31, 2012.
	Book values							Approximate  fair
								values
(in millions)	2013				2012			2013				2012
Assets
Long-term insurance receivables	$	2			$	2		$	2			$	2
Investments		52				46			53				49
Liabilities
Short-term debt		42				27			42				27
Current maturities of long-term debt and lease obligations		372				323			377				324
Long-term debt and lease obligations		8,652				5,580			8,930				6,201
Long-term litigation liabilities		53				32			52				31
The following tables summarize the bases used to measure the approximate fair value of the financial instruments as of September 30, 2013 and December 31, 2012.
					Basis of fair value measurement
(in millions)	Fair value as of				Quoted prices in			Significant other				Significant
	September 30, 2013				active markets for			observable inputs				unobservable
					identical assets			(Level 2)				inputs
					(Level 1)							(Level 3)
Assets
Long-term insurance receivables		$        2				$—			$        2				$—
Investments		53				—			18				35
Total assets		$      55				$—			$      20				$35
Liabilities
Short-term debt		$      42				$—			$      42				$—
Current maturities of long-term debt and lease obligations		377				—			377				—
Long-term debt and lease obligations		8,930				—			8,930				—
Long-term litigation liabilities		52				—			52				—
Total liabilities		$ 9,401				$—			$ 9,401				$—
					Basis of fair value measurement
(in millions)	Fair value as of				Quoted prices in			Significant other				Significant
	December 31, 2012				active markets for			observable inputs				unobservable
					identical assets			(Level 2)				inputs
					(Level 1)							(Level 3)
Assets
Long-term insurance receivables		$        2				$—			$        2				$—
Investments		49				—			19				30
Total assets		$      51				$—			$      21				$30
Liabilities
Short-term debt		$      27				$—			$      27				$—
Current maturities of long-term debt and lease obligations		324				—			324				—
Long-term debt and lease obligations		6,201				—			6,201				—
Long-term litigation liabilities		31				—			31				—
Total liabilities		$ 6,583				$—			$ 6,583				$—
The estimated fair values of long-term insurance receivables and long-term litigation liabilities were computed by discounting the expected cash flows based on currently available information, which in many cases does not include final orders or settlement agreements. The discount factors used in the calculations reflect the non-performance risk of the insurance providers and the company, respectively.
Investments in 2013 and 2012 included certain cost method investments and held-to-maturity debt securities.
The fair value of held-to-maturity debt securities is calculated using a discounted cash flow model that incorporates observable inputs, including interest rate yields, which represents a Level 2 basis of fair value measurement.
In determining the fair value of cost method investments, the company takes into consideration recent transactions, as well as the financial information of the investee, which represents a Level 3 basis of fair value measurement.
The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instrument. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with the company’s credit risk.

Shareholders_Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2013
Shareholders' Equity	8. SHAREHOLDERS’ EQUITY
	Stock-based compensation
	Stock compensation expense totaled $39 million and $34 million for the three months ended September 30, 2013 and 2012, respectively, and $111 million and $97 million for the nine months ended September 30, 2013 and 2012, respectively. Over 70% of stock compensation expense is classified in marketing and administrative expenses with the remainder classified in cost of sales and R&D expenses.
	In March 2013, the company awarded its annual stock compensation grants, which consisted of 6.2 million stock options, 852,000 RSUs and 376,000 PSUs. Stock compensation grants made in the second and third quarters of 2013 were not material.
	Stock Options
	The fair value of stock options is determined using the Black-Scholes model. The company’s expected volatility assumption is based on a weighted-average of the historical volatility of Baxter’s stock and the implied volatility from traded options on Baxter’s stock, with historical volatility more heavily weighted.
	The weighted-average assumptions used in estimating the fair value of stock options granted during the period, along with the weighted-average grant-date fair values, were as follows.
		Nine months ended
		September 30,
			2013		2012
	Expected volatility		25%		25%
	Expected life (in years)		5.5		5.5
	Risk-free interest rate		0.90%		1.00%
	Dividend yield		2.60%		2.30%
	Fair value per stock option		$12		$10
	The total intrinsic value of stock options exercised was $60 million and $34 million during the third quarters of 2013 and 2012, respectively, and $167 million and $67 million during the nine months ended September 30, 2013 and 2012, respectively.
	As of September 30, 2013, the unrecognized compensation cost related to all unvested stock options of $74 million is expected to be recognized as expense over a weighted-average period of 1.6 years.
	Restricted Stock Units
	The fair value of RSUs is determined based on the quoted price of the company’s common stock on the date of the grant. As of September 30, 2013, the unrecognized compensation cost related to all unvested RSUs of $82 million is expected to be recognized as expense over a weighted-average period of 1.9 years.
	Performance Share Units
	As part of an overall periodic evaluation of the company’s stock compensation programs, the company changed the vesting condition for 50% of the PSUs granted to senior management beginning with its 2013 annual equity awards. The vesting condition for the new PSUs is based on return on invested capital, with annual performance targets set at the beginning of the year for each tranche of the award during the three-year service period. The remaining 50% of the PSUs continued to include conditions for vesting based on Baxter stock performance relative to the company’s peer group, similar to previous years.
	Compensation cost for the new PSUs is measured based on the fair value of the awards on the date that the specific vesting terms for each tranche of the award are established. The fair value of the awards is determined based on the quoted price of the company’s stock on the grant date for each tranche of the award. The compensation cost for these PSUs is adjusted at each reporting date to reflect the estimated probability of achieving the vesting condition. The probability of achieving the vesting condition has not materially changed during the second and the third quarter of 2013.
	The fair value of the remaining PSUs continues to be determined using a Monte Carlo model. The assumptions used in estimating the fair value of these PSUs granted during the period, along with the grant-date fair values, were as follows.
		Nine months ended
		September 30,
		2013		2012
	Baxter volatility		21%		24%
	Peer group volatility		13% – 38%		14% – 50%
	Correlation of returns		0.37 – 0.62		0.26 – 0.54
	Risk-free interest rate		0.30%		0.40%
	Fair value per PSU		$67		$72
	As of September 30, 2013, the unrecognized compensation cost related to all granted unvested PSUs of $20 million is expected to be recognized as expense over a weighted-average period of 1.3 years.
	Dividends
	Cash dividend payments totaled $757 million and $558 million in the first nine months 2013 and 2012, respectively. The increase in cash dividend payments was primarily due to an increase in the quarterly dividend rate of approximately 9% to $0.49 per share, as announced in May 2013, and the July 2012 quarterly dividend rate increase of approximately 34% to $0.45 per share, partially offset by the impact of fewer common shares outstanding as a result of the company’s stock repurchase program. In July 2013, the board of directors declared a quarterly dividend of $0.49 per share, consistent with the May 2013 increase, which was paid on October 1, 2013 to shareholders of record as of September 6, 2013.
	Stock repurchases
	As authorized by the board of directors, the company repurchases its stock depending upon the company’s cash flows, net debt level and market conditions. During the three- and nine-month periods ended September 30, 2013, the company repurchased 2.0 million shares and 12.4 million shares for $145 million and $863 million, respectively, under the board of directors’ July 2012 $2.0 billion share repurchase authorization. As of September 30, 2013, $1.1 billion remained available under the July 2012 authorization.

Retirement_and_Other_Benefit_P

Retirement and Other Benefit Programs	9 Months Ended
	Sep. 30, 2013
Retirement and Other Benefit Programs	9. RETIREMENT AND OTHER BENEFIT PROGRAMS
	The following is a summary of net periodic benefit cost relating to the company’s pension and other postemployment benefit (OPEB) plans.
		Three months ended						Nine months ended
		September 30,						September 30,
	(in millions)	2013			2012			2013			2012
	Pension benefits
	Service cost		$34			$28			$101			$  83
	Interest cost		52			58			154			176
	Expected return on plan assets		(63	)		(72	)		(190	)		(216	)
	Amortization of net losses and other deferred amounts		61			52			184			156
	Net periodic pension benefit cost		$84			$66			$249			$199
	OPEB
	Service cost		$  2			$  2			$    7			$    5
	Interest cost		6			8			19			22
	Amortization of net loss and prior service credit		3			1			7			5
	Net periodic OPEB cost		$11			$11			$  33			$  32

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Taxes	10. INCOME TAXES
	Effective tax rate
	The company’s effective income tax rate was 20.2% and 23.9% in the three-month periods ended September 30, 2013 and 2012, respectively, and 20.4% and 20.9% in the nine-month periods ended September 30, 2013 and 2012, respectively. The company’s effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate. In addition, the effective tax rate can be impacted each period by discrete factors and events.
	The effective tax rate during the third quarter and first nine months of 2013 decreased primarily as a result of deductions and associated tax benefits at rates higher than the overall company’s effective tax rate. Specifically, the company recorded tax and legal reserves of $104 million, net of related benefits from noncontrolling interests, in the third quarter associated with VAT matters in Turkey and existing class action and other related litigation that had a favorable impact on the overall company’s effective tax rate. For the first nine months of 2013, the company also recorded a currency-related charge of $52 million primarily related to derivative instruments to hedge the anticipated foreign currency cash outflows for the acquisition of Gambro that had a favorable impact on the overall company’s effective tax rate.
	The company’s effective tax rate in the first nine months of 2012 was favorably impacted by reductions of contingent payment liabilities for milestones associated with the prior acquisitions of Prism Pharmaceuticals, Inc. (Prism) and ApaTech Limited, for which there was no tax charge, and a cost of sales reduction of $37 million for an adjustment to the COLLEAGUE infusion pump reserves as the company substantially completed the recall in the United States, for which there was no tax charge.
	Unrecognized tax benefits
	The company reduced its gross unrecognized tax benefits by approximately $153 million during the period ended September 30, 2013, related primarily to the effective settlement of the bilateral Advance Pricing Agreements between the US government and the government of Switzerland related to intellectual property, product and service transfer pricing arrangements, which was partially offset by other tax items associated with the company’s joint venture in Turkey.

Legal_Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2013
Legal Proceedings	11. LEGAL PROCEEDINGS
	Baxter is involved in product liability, patent, commercial, and other legal matters that arise in the normal course of the company’s business. The company records a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of September 30, 2013, the company’s total recorded reserves with respect to legal matters were $160 million and the total related receivables were $9 million.
	Baxter has established reserves for certain of the matters discussed below. The company is not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While the liability of the company in connection with the claims cannot be estimated with any certainty and although the resolution in any reporting period of one or more of these matters could have a significant impact on the company’s results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on the company’s consolidated financial position. While the company believes that it has valid defenses in these matters, litigation is inherently uncertain, excessive verdicts do occur, and the company may incur material judgments or enter into material settlements of claims.
	In addition to the matters described below, the company remains subject to other potential administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on the company’s operations and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, the company may be exposed to significant litigation concerning the scope of the company’s and others’ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations.
	Patent litigation
	As further described in Note 13 to the company’s consolidated financial statements in the 2012 Annual Report, Baxter filed a patent infringement action against Fresenius Medical Care Holdings covering Fresenius’ 2008K hemodialysis instrument. Fresenius appealed to the Federal Circuit whether Baxter may collect an award of $9 million in royalties and past damages and interest of $20 million in light of a United States Patent and Trademark Office determination with respect to patent invalidity. On July 2, 2013, the Federal Circuit ruled in favor of Fresenius and ordered that Baxter’s claims be dismissed. On August 1, 2013, Baxter filed a petition for rehearing en banc.
	Product liability litigation
	In connection with the recall of heparin products in the United States, approximately 130 lawsuits remain pending alleging that plaintiffs suffered various reactions to a heparin contaminant, in some cases resulting in fatalities. The vast majority of these cases are subject to settlement agreements but remain pending while settlement documentation is being completed.
	General litigation
	Baxter is a defendant in a number of suits alleging that certain of the company’s current and former executive officers and its board of directors failed to adequately oversee the operations of the company and issued materially false and misleading statements regarding the company’s plasma-based therapies business, the company’s remediation of its COLLEAGUE infusion pumps, its heparin product, and other quality issues. Plaintiffs allege these actions damaged the company and its shareholders by resulting in a decline in stock price in the second quarter of 2010, payment of excess compensation to the board of directors and certain of the company’s current and former executive officers, and other damage to the company. In August 2013, the U.S. Court of Appeals for the Seventh Circuit reinstated a consolidated derivative suit filed in the U.S.D.C. for the Northern District of Illinois that had earlier been dismissed by the district court in September 2012. Baxter is petitioning the U.S. Supreme Court to consider an appeal of that decision. Two derivative actions have been filed in state court: one pending in the Circuit Court of Lake County, Illinois has been stayed pending the outcome of the federal action and another, in Delaware Chancery Court, that Baxter has moved to dismiss. In addition, a consolidated alleged class action is pending in the U.S.D.C. for the Northern District of Illinois against the company and certain of its current executive officers seeking to recover the lost value of investors’ stock. In April 2013, the company filed its opposition to the plaintiff’s motion to certify a class action.
	The company is a defendant, along with others, in a number of lawsuits consolidated for pretrial proceedings in the U.S.D.C. for the Northern District of Illinois alleging that Baxter and certain of its competitors conspired to restrict output and artificially increase the price of plasma-derived therapies since 2003. Some of the complaints attempt to state a claim for class action relief and some cases demand treble damages. In February 2011, the court denied the company’s motion to dismiss certain of the claims and the parties are proceeding with discovery. In January 2012, the court granted the company’s motion to dismiss certain federal claims brought by indirect purchasers and returned the remaining indirect purchaser claims to the court of original jurisdiction (U.S.D.C. for the Northern District of California) in August 2012. The indirect purchaser complaint was amended to remove class action allegations in May 2013. The direct purchaser plaintiffs asked the court to certify a class action in September 2013. In October 2013, a co-defendant announced a $64 million dollar settlement of claims against itself and an industry association, the other remaining defendant in the case.
	Other
	The company has received an inquiry from the U.S. Department of Justice and the SEC requesting that the company provide information about its business activities in a number of countries. The company is cooperating with the agencies and understands that this inquiry is part of a broader review of industry practices for compliance with the U.S. Foreign Corrupt Practices Act.
	In the fourth quarter of 2012, the company received two investigative demands from the United States Attorney for the Western District of North Carolina for information regarding its quality and manufacturing practices and procedures at its North Cove facility. The company is fully cooperating with this investigation.

Segment_Information

Segment Information	9 Months Ended
	Sep. 30, 2013
Segment Information	12. SEGMENT INFORMATION
	Baxter’s two segments, BioScience and Medical Products, are strategic businesses that are managed separately because each business develops, manufactures and markets distinct products and services. The segments and a description of their products and services are as follows:
	The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines.
	The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed and oncology drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, infusion pumps, IV nutrition products and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, the Medical Products business provides products and services to treat end-stage renal disease, or irreversible kidney failure. The business manufactures solutions and other products for peritoneal dialysis, a home-based therapy, and also manufactures and distributes products for hemodialysis, which is generally conducted in a hospital or clinic. Effective September 2013, the Medical Products business includes the results of Gambro.
	The company uses more than one measurement and multiple views of data to measure segment performance and to allocate resources to the segments. However, the dominant measurements are consistent with the company’s condensed consolidated financial statements and, accordingly, are reported on the same basis in this report. The company evaluates the performance of its segments and allocates resources to them primarily based on pre-tax income along with cash flows and overall economic returns. Intersegment sales are generally accounted for at amounts comparable to sales to unaffiliated customers, and are eliminated in consolidation.
	Certain items are maintained at Corporate and are not allocated to a segment. They primarily include most of the company’s debt and cash and equivalents and related net interest expense, certain foreign exchange fluctuations (principally relating to intercompany receivables, payables and loans denominated in a foreign currency) and the majority of the foreign currency hedging activities, corporate headquarters costs, stock compensation expense, certain non-strategic investments and related income and expense, certain employee benefit plan costs, certain nonrecurring gains and losses, deferred income taxes, and certain litigation liabilities and related receivables.
	Financial information for the company’s segments is as follows.
		Three months ended						Nine months ended
		September 30,						September 30,
	(in millions)	2013			2012			2013			2012
	Net sales
	BioScience	$	1,620		$	1,522		$	4,788		$	4,550
	Medical Products		2,154			1,955			6,103			5,887
	Total net sales	$	3,774		$	3,477		$	10,891		$	10,437
	Pre-tax income
	BioScience	$	615		$	537		$	1,851		$	1,605
	Medical Products		343			388			1,038			1,214
	Total pre-tax income from segments	$	958		$	925		$	2,889		$	2,819
	The following is a reconciliation of segment pre-tax income to income before income taxes per the condensed consolidated statements of income.
		Three months ended						Nine months ended
		September 30,						September 30,
	(in millions)	2013			2012			2013			2012
	Total pre-tax income from segments		$958			$925			$2,889			$2,819
	Unallocated amounts
	Stock compensation		(39	)		(34	)		(111	)		(97	)
	Net interest expense		(45	)		(25	)		(87	)		(65	)
	Certain foreign currency fluctuations and hedging activities		21			13			63			33
	Certain tax and legal reserves		(104	)		—			(104	)		—
	Other Corporate items		(109	)		(113	)		(532	)		(375	)
	Income before income taxes		$682			$766			$2,118			$2,315

Supplemental_Financial_Informa1

Supplemental Financial Information (Tables)	9 Months Ended
	Sep. 30, 2013
Net Interest Expense	Net interest expense
			Three months ended						Nine months ended
			September 30,						September 30,
	(in millions)		2013			2012			2013			2012
	Interest expense, net of capitalized interest			$51			$31			$106			$85
	Interest income			(6	)		(6	)		(19	)		(20	)
	Net interest expense			$45			$25			$  87			$65
Inventories	Inventories
	(in millions)		September 30,			December 31,
			2013			2012
	Raw materials			$   967			$   765
	Work in process			1,009			898
	Finished goods			1,605			1,140
	Inventories			$3,581			$2,803
Property, Plant and Equipment, Net	Property, plant and equipment, net
	(in millions)		September 30,			December 31,
			2013			2012
	Property, plant and equipment, at cost			$13,324			$11,869
	Accumulated depreciation and amortization			(5,806	)		(5,771	)
	Property, plant and equipment (PP&E), net			$  7,518			$  6,098
Summary of Changes in AOCI by Component	The following is a net-of-tax summary of the changes in AOCI by component for the nine months ended September 30, 2013.
	(in millions)		Currency			Pension and			Hedging			Other			Total
			translation			other employee			activities
			adjustments			benefits
	Gains (losses)
	Balance as of December 31, 2012			($1,227	)		($1,619	)		($  5	)		$41			($2,810	)
	Other comprehensive income before reclassifications			58			(5	)		44			12			109
	Amounts reclassified from AOCI (a)			—			124			(23	)		—			101
	Net other comprehensive income			58			119			21			12			210
	Balance as of September 30, 2013			($1,169	)		($1,500	)		$16			$53			($2,600	)
	(a)	See table below for details about the reclassifications for the nine months ended September 30, 2013.
Summary of Reclassification from AOCI to Net Income	The following is a summary of the amounts reclassified from AOCI to net income during the three and nine months ended September 30, 2013.
			Amounts reclassified from AOCI (a)
	(in millions)		Three months ended			Nine months ended			Location of impact in income statement
			September 30, 2013			September 30, 2013
	Amortization of pension and other employee benefits items
	Actuarial losses and other			($64	) (b)		($191	) (b)
				(64	)		(191	)	Total before tax
				23			67		Tax benefit
				($41	)		($124	)	Net of tax
	Gains (losses) on hedging activities
	Interest rate contracts			$ (1	)		$  10		Net interest expense
	Foreign exchange contracts			—			(1	)	Net sales
	Foreign exchange contracts			9			27		Cost of sales
				8			36		Total before tax
				(3	)		(13	)	Tax expense
				$  5			$  23		Net of tax
	Total reclassification for the period			($36	)		($101	)	Total net of tax
	(a)	Amounts in parentheses indicate reductions to net income.
	(b)	These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 9.

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Reconciliation of Basic Shares to Diluted Shares	The following is a reconciliation of basic shares to diluted shares.
		Three months ended				Nine months ended
		September 30,				September 30,
	(in millions)	2013		2012		2013		2012
	Basic shares		543		548		543		552
	Effect of dilutive securities		6		4		7		4
	Diluted shares		549		552		550		556

Acquisitions_and_Collaboration1

Acquisitions and Collaborations (Tables)	9 Months Ended
	Sep. 30, 2013
Summary of Fair Value of Consideration Transferred and Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed	The following table summarizes the fair value of the consideration transferred and the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date.
	(in millions)
	Consideration transferred
	Cash	$	3,704
	Fair value of consideration transferred	$	3,704
	Assets acquired and liabilities assumed
	Cash	$	88
	Accounts receivable		483
	Inventories		367
	Prepaid expenses and other		54
	Property, plant, and equipment		854
	Other intangible assets		1,650
	Other assets		11
	Current-maturities of long-term debt and lease obligations		(2	)
	Accounts payable and accrued liabilities		(334	)
	Long-term debt and lease obligations		(261	)
	Other long-term liabilities (including pension obligations of $214)		(458	)
	Total identifiable net assets		2,452
	Goodwill		1,252
	Total assets acquired and liabilities assumed	$	3,704
Subsidiary Information in Consolidated Statement of Income from Acquisition	The following table presents information for Gambro that is included in Baxter’s consolidated statement of income from the acquisition date through September 30, 2013.
	(in millions)	Gambro’s operations
		included in Baxter’s
		results
	Net sales		$100
	Net loss		$ (17	)
Supplemental Pro Forma Information	The following table presents supplemental pro forma information as if the acquisition of Gambro had occurred on January 1, 2012 for the three and nine months ended September 30, 2013 and 2012.
		Unaudited Pro Forma Consolidated Results
		Three months ended					Nine months ended
		September 30,					September 30,
	(in millions, except per share information)	2013			2012		2013		2012
	Net sales	$	4,038		$	3,855	$	11,933	$	11,594
	Net income		547			568		1,713		1,613
	Basic earnings per share	$	1.01		$	1.04	$	3.16	$	2.92
	Diluted earnings per share	$	1		$	1.03	$	3.11	$	2.9
Summary of Fair Value of Consideration Transferred and Recognized Amounts of Assets Acquired and Liabilities Assumed	The following table summarizes the updated estimated fair value of consideration transferred and the recognized amounts of the assets acquired and liabilities assumed as of the acquisition date for the Inspiration / Ipsen OBI-1 business.
	(in millions)
	Consideration transferred
	Cash		$  51
	Contingent payments		269
	Fair value of consideration transferred		$320
	Assets acquired and liabilities assumed
	Other intangible assets		$288
	Other assets, net		25
	Goodwill		7
	Total assets acquired and liabilities assumed		$320

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill	The following is a reconciliation of goodwill by business segment.
	(in millions)	BioScience			Medical			Total
					Products
	Balance as of December 31, 2012		$975			$1,527			$2,502
	Additions		7			1,254			1,261
	Currency translation and other adjustments		4			13			17
	Balance as of September 30, 2013		$986			$2,794			$3,780
Other Intangible Assets, Net	The following is a summary of the company’s other intangible assets.
	(in millions)	Developed technology,			Other amortized			Indefinite-lived		Total
		including patents			intangible assets			intangible  assets
	September 30, 2013
	Gross other intangible assets		$2,850			$281			$309		$3,440
	Accumulated amortization		(630	)		(128	)		—		(758	)
	Other intangible assets, net		$2,220			$153			$309		$2,682
	December 31, 2012
	Gross other intangible assets		$1,192			$280			$  22		$1,494
	Accumulated amortization		(578	)		(102	)		—		(680	)
	Other intangible assets, net		$   614			$178			$  22		$   814

Infusion_Pump_and_Business_Opt1

Infusion Pump and Business Optimization Charges (Tables)	9 Months Ended
	Sep. 30, 2013
Infusion Pump Charges	The following table summarizes cash activity in the company’s COLLEAGUE infusion pump reserves through September 30, 2013.
	(in millions)
	Reserves as of December 31, 2012	$127
	Utilization	(20	)
	Reserves as of September 30, 2013	$107
Business Optimization Charge	The following table summarizes cash activity in the reserves related to the company’s business optimization initiatives.
	(in millions)
	Reserves as of December 31, 2012	$220
	Charges	32
	Reserve adjustments	(20	)
	Utilization	(61	)
	CTA	3
	Reserves as of September 30, 2013	$174

Debt_Financial_Instruments_and1

Debt, Financial Instruments and Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Summary of Activity Relating to Securitization Arrangement	The following is a summary of the activity relating to the company’s securitization arrangement in Japan.
		Three months ended							Nine months ended
		September 30,							September 30,
	(in millions)	2013				2012			2013				2012
	Sold receivables at beginning of period		$  129				$  154			$  157				$  160
	Proceeds from sales of receivables		125				161			380				461
	Cash collections (remitted to the owners of the receivables)		(130	)			(161	)		(394	)			(465	)
	Effect of currency exchange rate changes		(6	)			—			(25	)			(2	)
	Sold receivables at end of period		$  118				$  154			$  118				$  154
Summary of Gains and Losses on Derivative Instruments	The following table summarizes the income statement locations and gains and losses on the company’s derivative instruments for the three months ended September 30, 2013 and 2012.
		Gain (loss) recognized in OCI							Location of gain (loss) in		Gain (loss) reclassified from AOCI
									income statement		into income
	(in millions)	2013				2012					2013				2012
	Cash flow hedges
	Interest rate contracts		$—				$  (3	)	Net interest expense			$  (1	)			$—
	Foreign exchange contracts		(1	)			(1	)	Net sales			—				(1	)
	Foreign exchange contracts		7				(20	)	Cost of sales			9				5
	Total		$  6				$(24	)				$   8				$  4
											Gain (loss) recognized in income
	(in millions)								Location of gain (loss) in		2013				2012
									income statement
	Fair value hedges
	Interest rate contracts								Net interest expense			$  1				$  5
	Undesignated derivative instruments
	Foreign exchange contracts								Other (income) expense, net			$51				$ (2	)
	The following table summarizes the income statement locations and gains and losses on the company’s derivative instruments for the nine months ended September 30, 2013 and 2012.
		Gain (loss) recognized in OCI							Location of gain (loss) in		Gain (loss) reclassified from
									income statement		AOCI into income
	(in millions)	2013				2012					2013				2012
	Cash flow hedges
	Interest rate contracts		$26				$(12	)	Net interest expense			$10				$ —
	Foreign exchange contracts		(1	)			(2	)	Net sales			(1	)			(2	)
	Foreign exchange contracts		43				(11	)	Cost of sales			27				4
	Total		$68				$(25	)				$36				$   2
											Gain (loss) recognized in income
	(in millions)								Location of gain (loss) in		2013				2012
									income statement
	Fair value hedges
	Interest rate contracts								Net interest expense			$(25	)			$ 15
	Undesignated derivative instruments
	Foreign exchange contracts								Other (income) expense, net			$   6				$(13	)
Classification and Fair Value Amounts of Derivative Instruments	The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of September 30, 2013.
		Derivatives in asset positions						Derivatives in liability positions
	(in millions)	Balance sheet location		Fair value				Balance sheet location	Fair value
	Derivative instruments designated as hedges
	Interest rate contracts	Other long-term assets			$  42			Other long-term liabilities		$—
	Foreign exchange contracts	Prepaid expenses and other			46			Accounts payable		6
								and accrued liabilities
	Foreign exchange contracts	Other long-term assets			8			Other long-term liabilities		1
	Total derivative instruments designated as hedges				$  96					$  7
	Undesignated derivative instruments
	Foreign exchange contracts	Prepaid expenses and other			$  —			Accounts payable		$  1
								and accrued liabilities
	Total derivative instruments				$  96					$  8
	The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2012.
		Derivatives in asset positions						Derivatives in liability positions
	(in millions)	Balance sheet location		Fair value				Balance sheet location	Fair value
	Derivative instruments designated as hedges
	Interest rate contracts	Other long-term assets			$  67			Accounts payable		$21
								and accrued liabilities
	Foreign exchange contracts	Prepaid expenses and other			28			Accounts payable		5
								and accrued liabilities
	Total derivative instruments designated as hedges				$  95					$26
	Undesignated derivative instruments
	Foreign exchange contracts	Prepaid expenses and other			$  47			Accounts payable		$11
								and accrued liabilities
	Total derivative instruments				$142					$37
Derivative Positions Presented on Net Basis	The following table provides information on the company’s derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty.
		September 30, 2013							December 31, 2012
	(in millions)	Asset				Liability			Asset				Liability
	Gross amounts recognized in the consolidated balance sheet		$96				$  8			$142				$37
	Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet		(8	)			(8	)		(37	)			(37	)
	Total		$88				$—			$105				$—
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables summarize the bases used to measure financial assets and liabilities that are carried at fair value on a recurring basis in the condensed consolidated balance sheets.
						Basis of fair value measurement
	(in millions)	Balance as of				Quoted prices in			Significant other				Significant
		September 30, 2013				active markets for			observable inputs				unobservable
						identical assets			(Level 2)				inputs
						(Level 1)							(Level 3)
	Assets
	Foreign currency hedges		$  54				$  —			$  54				$  —
	Interest rate hedges		42				—			42				—
	Available-for-sale securities
	Equity securities		110				110			—				—
	Foreign government debt securities		17				—			17				—
	Total assets		$223				$110			$113				$  —
	Liabilities
	Foreign currency hedges		$    8				$  —			$    8				$  —
	Contingent payments related to acquisitions		344				—			—				344
	Total liabilities		$352				$  —			$    8				$344
						Basis of fair value measurement
	(in millions)	Balance as of				Quoted prices in			Significant other				Significant
		December 31, 2012				active markets for			observable inputs				unobservable
						identical assets			(Level 2)				inputs
						(Level 1)							(Level 3)
	Assets
	Foreign currency hedges		$  75				$—			$  75				$—
	Interest rate hedges		67				—			67				—
	Available-for-sale securities
	Equity securities		15				15			—				—
	Preferred stock		51				—			—				51
	Foreign government debt securities		16				—			16				—
	Total assets		$224				$15			$158				$51
	Liabilities
	Foreign currency hedges		$  16				$—			$  16				$—
	Interest rate hedges		21				—			21				—
	Contingent payments related to acquisitions		86				—			—				86
	Total liabilities		$123				$—			$  37				$86
Reconciliation of Fair Value Measurements that use Significant Unobservable Inputs	The following table is a reconciliation of the fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions and preferred stock.
	(in millions)	Contingent				Preferred
		payments				stock
	Fair value as of December 31, 2012		$  86				$51
	Additions		269				—
	Payments		(2	)			—
	Gains recognized in earnings		(9	)			—
	Conversion to a publicly traded equity security		—				(51	)
	Fair value as of September 30, 2013		$344				$—
Book Values and Fair Values of Financial Instruments	For these financial instruments, the following table provides the values recognized in the condensed consolidated balance sheets and the approximate fair values as of September 30, 2013 and December 31, 2012.
		Book values							Approximate  fair
									values
	(in millions)	2013				2012			2013				2012
	Assets
	Long-term insurance receivables	$	2			$	2		$	2			$	2
	Investments		52				46			53				49
	Liabilities
	Short-term debt		42				27			42				27
	Current maturities of long-term debt and lease obligations		372				323			377				324
	Long-term debt and lease obligations		8,652				5,580			8,930				6,201
	Long-term litigation liabilities		53				32			52				31
Summarization of Bases Used to Measure Fair Value of Financial Instruments	The following tables summarize the bases used to measure the approximate fair value of the financial instruments as of September 30, 2013 and December 31, 2012.
						Basis of fair value measurement
	(in millions)	Fair value as of				Quoted prices in			Significant other				Significant
		September 30, 2013				active markets for			observable inputs				unobservable
						identical assets			(Level 2)				inputs
						(Level 1)							(Level 3)
	Assets
	Long-term insurance receivables		$        2				$—			$        2				$—
	Investments		53				—			18				35
	Total assets		$      55				$—			$      20				$35
	Liabilities
	Short-term debt		$      42				$—			$      42				$—
	Current maturities of long-term debt and lease obligations		377				—			377				—
	Long-term debt and lease obligations		8,930				—			8,930				—
	Long-term litigation liabilities		52				—			52				—
	Total liabilities		$ 9,401				$—			$ 9,401				$—
						Basis of fair value measurement
	(in millions)	Fair value as of				Quoted prices in			Significant other				Significant
		December 31, 2012				active markets for			observable inputs				unobservable
						identical assets			(Level 2)				inputs
						(Level 1)							(Level 3)
	Assets
	Long-term insurance receivables		$        2				$—			$        2				$—
	Investments		49				—			19				30
	Total assets		$      51				$—			$      21				$30
	Liabilities
	Short-term debt		$      27				$—			$      27				$—
	Current maturities of long-term debt and lease obligations		324				—			324				—
	Long-term debt and lease obligations		6,201				—			6,201				—
	Long-term litigation liabilities		31				—			31				—
	Total liabilities		$ 6,583				$—			$ 6,583				$—

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Stock Options Fair Value Assumptions	The weighted-average assumptions used in estimating the fair value of stock options granted during the period, along with the weighted-average grant-date fair values, were as follows.
		Nine months ended
		September 30,
			2013		2012
	Expected volatility		25%		25%
	Expected life (in years)		5.5		5.5
	Risk-free interest rate		0.90%		1.00%
	Dividend yield		2.60%		2.30%
	Fair value per stock option		$12		$10
Performance Stock Units Fair Value	The fair value of the remaining PSUs continues to be determined using a Monte Carlo model. The assumptions used in estimating the fair value of these PSUs granted during the period, along with the grant-date fair values, were as follows.
		Nine months ended
		September 30,
		2013		2012
	Baxter volatility		21%		24%
	Peer group volatility		13% – 38%		14% – 50%
	Correlation of returns		0.37 – 0.62		0.26 – 0.54
	Risk-free interest rate		0.30%		0.40%
	Fair value per PSU		$67		$72

Retirement_and_Other_Benefit_P1

Retirement and Other Benefit Programs (Tables)	9 Months Ended
	Sep. 30, 2013
Net Periodic Benefit Cost Relating to Pension and Other Postemployement Benefit	The following is a summary of net periodic benefit cost relating to the company’s pension and other postemployment benefit (OPEB) plans.
		Three months ended						Nine months ended
		September 30,						September 30,
	(in millions)	2013			2012			2013			2012
	Pension benefits
	Service cost		$34			$28			$101			$  83
	Interest cost		52			58			154			176
	Expected return on plan assets		(63	)		(72	)		(190	)		(216	)
	Amortization of net losses and other deferred amounts		61			52			184			156
	Net periodic pension benefit cost		$84			$66			$249			$199
	OPEB
	Service cost		$  2			$  2			$    7			$    5
	Interest cost		6			8			19			22
	Amortization of net loss and prior service credit		3			1			7			5
	Net periodic OPEB cost		$11			$11			$  33			$  32

Segment_Information_Tables

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Information	Financial information for the company’s segments is as follows.
		Three months ended						Nine months ended
		September 30,						September 30,
	(in millions)	2013			2012			2013			2012
	Net sales
	BioScience	$	1,620		$	1,522		$	4,788		$	4,550
	Medical Products		2,154			1,955			6,103			5,887
	Total net sales	$	3,774		$	3,477		$	10,891		$	10,437
	Pre-tax income
	BioScience	$	615		$	537		$	1,851		$	1,605
	Medical Products		343			388			1,038			1,214
	Total pre-tax income from segments	$	958		$	925		$	2,889		$	2,819
Pre-Tax Income Reconciliation	The following is a reconciliation of segment pre-tax income to income before income taxes per the condensed consolidated statements of income.
		Three months ended						Nine months ended
		September 30,						September 30,
	(in millions)	2013			2012			2013			2012
	Total pre-tax income from segments		$958			$925			$2,889			$2,819
	Unallocated amounts
	Stock compensation		(39	)		(34	)		(111	)		(97	)
	Net interest expense		(45	)		(25	)		(87	)		(65	)
	Certain foreign currency fluctuations and hedging activities		21			13			63			33
	Certain tax and legal reserves		(104	)		—			(104	)		—
	Other Corporate items		(109	)		(113	)		(532	)		(375	)
	Income before income taxes		$682			$766			$2,118			$2,315

Basis_Of_Presentation_Addition

Basis Of Presentation - Additional Information (Detail) (Gambro, USD $)	Sep. 06, 2013
In Millions, unless otherwise specified
Gambro
Organization And Summary Of Significant Accounting Policies [Line Items]
Cash consideration for the acquisition	$3,704
Assumed debt	$221

Net_Interest_Expense_Detail

Net Interest Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Interest Income Expense Net
Interest expense, net of capitalized interest	$51	$31	$106	$85
Interest income	-6	-6	-19	-20
Net interest expense	$45	$25	$87	$65

Inventories_Detail

Inventories (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Inventory
Raw materials	$967	$765
Work in process	1,009	898
Finished goods	1,605	1,140
Inventories	$3,581	$2,803

Property_Plant_and_Equipment_N

Property, Plant and Equipment ,Net (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Property, Plant and Equipment, Net
Property, plant and equipment, at cost	$13,324	$11,869
Accumulated depreciation and amortization	-5,806	-5,771
Property, plant and equipment (PP&E), net	$7,518	$6,098

Summary_of_Changes_in_AOCI_by_

Summary of Changes in AOCI by Component (Detail) (USD $)	3 Months Ended			9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012	Sep. 30, 2013		Sep. 30, 2012
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Currency translation adjustment, Balance as of December 31, 2012				($1,227)
Currency translation adjustment, other comprehensive income before reclassifications				58
Currency translation adjustment, amounts reclassified from AOCI					[1]
Currency translation adjustment, net other comprehensive income	112		180	58		-41
Currency translation adjustment, Balance as of September 30, 2013	-1,169			-1,169
Pension and other employee benefit Balance as of December 31, 2012				-1,619
Pension and other employee benefit, Other comprehensive income before reclassifications				-5
Pension and other employee benefit, Amounts reclassified from AOCI				124	[1]
Pension and other employee benefit, Net other comprehensive income	42		28	119		101
Pension and other employee benefit Balance as of Balance as of September 30, 2013	-1,500			-1,500
Hedging activities, Balance as of December 31, 2012				-5
Hedging activities, Other comprehensive income before reclassifications				44
Hedging activities, Amounts reclassified from AOCI	-5	[2]		-23	[1],[2]
Hedging activities, Net other comprehensive income	-2		-18	21		-17
Hedging activities, Balance as of September 30, 2013	16			16
Other, Balance as of December 31, 2012				41
Other, Other comprehensive income before reclassifications				12
Other, Amounts reclassified from AOCI					[1]
Other, Net other comprehensive income	13		-2	12		-1
Other, Balance as of September 30, 2013	53			53
Total, Balance as of December 31, 2012				-2,810
Total, Other comprehensive income before reclassifications				109
Total, Amounts reclassified from AOCI				101	[1]
Total, Net other comprehensive income	165		188	210		42
Total, Balance as of September 30, 2013	($2,600)			($2,600)
[1]	See table below for details about the reclassifications for the nine months ended September 30, 2013.
[2]	Amounts in parentheses indicate reductions to net income.

Summary_of_Amounts_Reclassifie

Summary of Amounts Reclassified from AOCI to Net Income (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2013
Other Comprehensive Income (Loss) [Line Items]
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, before tax	($64)	[1]	($191)	[1]
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, tax benefit	23	[1]	67	[1]
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, Net of tax	-41	[1]	-124	[1]
Gain (Loss) on hedging activities reclassified from AOCI to net income, before tax	8	[1]	36	[1]
Gain on hedging activities reclassified from AOCI to net income, tax expense	-3	[1]	-13	[1]
Gain on hedging activities reclassified from AOCI to net income, Net of tax	5	[1]	23	[1],[2]
Total reclassification for the period	-36	[1]	-101	[1]
Interest Rate Contract | Interest Expense
Other Comprehensive Income (Loss) [Line Items]
Gain (Loss) on hedging activities reclassified from AOCI to net income, before tax	-1	[1]	10	[1]
Foreign Exchange Contract | Net Sales
Other Comprehensive Income (Loss) [Line Items]
Gain (Loss) on hedging activities reclassified from AOCI to net income, before tax			-1	[1]
Foreign Exchange Contract | Cost of Revenue
Other Comprehensive Income (Loss) [Line Items]
Gain (Loss) on hedging activities reclassified from AOCI to net income, before tax	9	[1]	27	[1]
Actuarial losses and other
Other Comprehensive Income (Loss) [Line Items]
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, before tax	($64)	[1],[3]	($191)	[1],[3]
[1]	Amounts in parentheses indicate reductions to net income.
[2]	See table below for details about the reclassifications for the nine months ended September 30, 2013.
[3]	These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 9.

Reconciliation_of_Basis_Shares

Reconciliation of Basis Shares to Diluted Shares (Detail)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Computation of earnings per share
Basic shares	543	548	543	552
Effect of dilutive securities	6	4	7	4
Diluted shares	549	552	550	556

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Computation Of Earnings Per Share Line Items
Anti-dilutive securities excluded from computation of EPS	6	17	5	22

Acquisitions_and_Collaboration2

Acquisitions and Collaborations - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Sep. 06, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Aug. 31, 2013

Aug. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 06, 2013

Purchase Price Allocation Adjustments

Purchase Price Allocation Adjustments

Gambro

Gambro

Gambro

Gambro

Gambro

Gambro

Gambro

Coherus Biosciences Collaboration

Coherus Development And Regulatory Milestones

Inspiration / Ipsen OBI-1 business

Inspiration / Ipsen OBI-1 business

Inspiration / Ipsen OBI-1 business

JW Holdings Regulatory Milestones and Royalties

JW Holdings Regulatory Milestones and Royalties

Indap Holding AB

Fair Value Adjustment to Inventory

Fair Value Adjustment to Inventory

Fair Value Adjustment to Inventory

Maximum

In-process research and development (IPR&D)

Regulatory and Sales Milestones

Maximum

Acquisitions And Collaborations [Line Items]

Voting interest acquired, percent

100.00%

Total cash payment for the acquisition

$3,704

$320

Assumed debt

221

Intangible assets, weighted average useful life

12 years 6 months

Repayment of assumed debt

221

Acquisition-related costs recorded in marketing and administrative expenses

14

18

58

Fair value adjustments for acquisition-date inventory

15

Elimination of acquisition costs

135

15

15

Additional acquisition costs

60

Business acquisition, cost of acquired entity, purchase price

3,704

51

Business acquisition contingent consideration

216

135

10

Change in consideration transferred

2

-58

Other intangible assets

-55

288

288

Goodwill

2

-3

1,252

7

Estimated fair value of contingent payment liabilities at acquisition date

269

Upfront payment recorded as a deposit asset

30

Research and development expense

$290

$290

$809

$865

$25

Summary_of_Fair_Value_of_Consi

Summary of Fair Value of Consideration Transferred and Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed (Detail) (Gambro, USD $)	Sep. 06, 2013
In Millions, unless otherwise specified
Gambro
Consideration transferred
Cash	$3,704
Fair value of consideration transferred	3,704
Assets acquired and liabilities assumed
Cash	88
Accounts receivable	483
Inventories	367
Prepaid expenses and other	54
Property, plant, and equipment	854
Other intangible assets	1,650
Other assets	11
Current-maturities of long-term debt and lease obligations	-2
Accounts payable and accrued liabilities	-334
Long-term debt and lease obligations	-261
Other long-term liabilities (including pension obligations of $214)	-458
Total identifiable net assets	2,452
Goodwill	1,252
Total assets acquired and liabilities assumed	$3,704

Summary_of_Fair_Value_of_Consi1

Summary of Fair Value of Consideration Transferred and Preliminary Amounts Recognized for Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) (Gambro, USD $)	Sep. 06, 2013
In Millions, unless otherwise specified
Gambro
Business Acquisition [Line Items]
Other long-term liabilities, pension obligations	$214

Subsidiary_Information_in_Cons

Subsidiary Information in Consolidated Statement of Income from Acquisition (Detail) (Gambro, USD $)	1 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Gambro
Business Acquisition, Impact on Operating Results [Line Items]
Net sales	$100
Net loss	($17)

Supplemental_Pro_Forma_Informa

Supplemental Pro Forma Information (Detail) (Gambro, USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Gambro
Business Acquisition, Pro Forma Information [Line Items]
Net sales	$4,038	$3,855	$11,933	$11,594
Net income	$547	$568	$1,713	$1,613
Basic earnings per share	$1.01	$1.04	$3.16	$2.92
Diluted earnings per share	$1	$1.03	$3.11	$2.90

Summary_of_Fair_Value_of_Consi2

Summary of Fair Value of Consideration Transferred and Recognized Amounts of Assets Acquired and Liabilities Assumed (Detail) (Inspiration / Ipsen OBI-1 business, USD $)	Mar. 31, 2013
In Millions, unless otherwise specified
Inspiration / Ipsen OBI-1 business
Consideration transferred
Cash	$51
Contingent payments	269
Fair value of consideration transferred	320
Assets acquired and liabilities assumed
Other intangible assets	288
Other assets, net	25
Goodwill	7
Total assets acquired and liabilities assumed	$320

Goodwill_Detail

Goodwill (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Goodwill [Line Items]
Goodwill,beginning balance	$2,502
Additions	1,261
Currency translation and other adjustments	17
Goodwill,ending balance	3,780
BioScience
Goodwill [Line Items]
Goodwill,beginning balance	975
Additions	7
Currency translation and other adjustments	4
Goodwill,ending balance	986
Medical Products
Goodwill [Line Items]
Goodwill,beginning balance	1,527
Additions	1,254
Currency translation and other adjustments	13
Goodwill,ending balance	$2,794

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets, Net - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Goodwill And Other Intangible Asset [Line Items]
Accumulated goodwill impairment losses	$0		$0
Amortization expense	34,000,000	26,000,000	84,000,000	76,000,000
Anticipated annual amortization expense of other intangible assets for 2013			142,000,000
Anticipated annual amortization expense of other intangible assets for 2014	227,000,000		227,000,000
Anticipated annual amortization expense of other intangible assets for 2015	225,000,000		225,000,000
Anticipated annual amortization expense of other intangible assets for 2016	222,000,000		222,000,000
Anticipated annual amortization expense of other intangible assets for 2017	204,000,000		204,000,000
Anticipated annual amortization expense of other intangible assets for 2018	$199,000,000		$199,000,000

Other_Intangible_Assets_Net_De

Other Intangible Assets, Net (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets	$3,440	$1,494
Accumulated amortization	-758	-680
Other intangible assets, net	2,682	814
Developed technology, including patents
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets	2,850	1,192
Accumulated amortization	-630	-578
Other intangible assets, net	2,220	614
Other amortized intangible assets
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets	281	280
Accumulated amortization	-128	-102
Other intangible assets, net	153	178
Indefinite-lived intangible assets
Intangible Asset Excluding Goodwill [Line Items]
Gross other intangible assets	309	22
Accumulated amortization
Other intangible assets, net	$309	$22

Infusion_Pump_and_Business_Opt2

Infusion Pump and Business Optimization Charges - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended	48 Months Ended	96 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2012
Restructuring Cost and Reserve [Line Items]
Total charges related to infusion pumps					$888
Infusion pump charges related to cash					742
Infusion pump charges related asset impairments					146
Infusion pump cash reserves	107		107	127	127
Costs associated with optimizing the cost structure				678
Cash portion of charges			32	507
Asset impairment charges				171
Cash reserves	174		174	220	220
Post-acquisition restructuring charge	14
Alzheimer's program Contract termination costs		-18
Reserve adjustments		($20)	($20)

Infusion_Pump_Charges_Detail

Infusion Pump Charges (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Infusion pump reserves
Reserves, beginning balance	$127
Utilization	-20
Reserves, ending balance	$107

Business_Optimization_Charges_

Business Optimization Charges (Detail) (USD $)	3 Months Ended	9 Months Ended	48 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2013	Sep. 30, 2013	Dec. 31, 2012
Business Optimization Initiatives
Reserve, beginning balance		$220
Charges		32	507
Reserve adjustments	-20	-20
Utilization		-61
CTA		3
Reserve, ending balance		$174	$220

Summary_of_Activity_Relating_t

Summary of Activity Relating to Securitization Arrangement (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Accounts Receivable Securitization [Line Items]
Sold receivables at beginning of period	$129	$154	$157	$160
Proceeds from sales of receivables	125	161	380	461
Cash collections (remitted to the owners of the receivables)	-130	-161	-394	-465
Effect of currency exchange rate changes	-6		-25	-2
Sold receivables at end of period	$118	$154	$118	$154

Debt_Financial_Instruments_and2

Debt, Financial Instruments and Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		1 Months Ended		1 Months Ended											3 Months Ended	9 Months Ended				1 Months Ended	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Jun. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2013	Jan. 31, 2013	Jun. 30, 2013
							Floating rate senior notes maturing in December 2014	Floating rate senior notes maturing in December 2014	Senior Notes Maturing in June Two Thousand Sixteen	Senior Notes Maturing in June Two Thousand Eighteen	Senior Notes Maturing in June Two Thousand Twenty Three	Senior Notes Due Two Thousand Forty Three	Primary and Euro-denominated	Primary and Euro-denominated	Terminated Fair Value Hedge	Countries With Liquidity Issues	Countries With Liquidity Issues	Maximum	Maximum	Gambro	Gambro	Gambro	Gambro	Gambro	Gambro	Gambro
																	GREECE	Debt Securities	Debt Securities					Countries With Liquidity Issues	Bridge Loan Facility	Bridge Loan Facility
Debt Instrument [Line Items]
Value of senior notes issued							$500,000,000		$500,000,000	$750,000,000	$1,250,000,000	$500,000,000
Higher rate of debt maturity periods							Dec-14		Jun-16	Jun-18	Jun-23	Jun-43
Senior notes, coupon rates									0.95%	1.85%	3.20%	4.50%
Senior notes, floating rate								0.43%
Net proceeds of debt to be used for acquisition																					3,000,000,000
Outstanding borrowings under credit facility													0	0
Commercial paper outstanding	0		0		0
Credit facility maximum capacity																									3,100,000,000
Bridge loan facility term																									364 days
Expense related bridge loan facility																										13,000,000
Total accounts receivable from certain countries with liquidity issues																559,000,000	43,000,000							141,000,000
Notional amount of cash flow hedge foreign exchange contracts	2,200,000,000		2,200,000,000		1,500,000,000
Interest rate contracts designated as cash flow hedge, Terminated amount	1,000,000,000		1,000,000,000		250,000,000
Maximum length of time hedge in cash flow hedge	15 months		15 months
Notional amount of interest rate fair value hedge derivatives	500,000,000		500,000,000		500,000,000										175,000,000
Gain on Cash Flow Hedge			5,000,000
Gain on Interest rate contracts designated as cash flow hedge			11,000,000
Remaining deferred net loss to be amortized to net interest expense			6,000,000
Deferred gain amortized over the remaining term of the hedged item		21,000,000		21,000,000
Total gross notional amount of undesignated derivative instruments	318,000,000		318,000,000		3,200,000,000																	1,500,000,000	3,700,000,000
Gambro derivative gain (loss)																				49,000,000	-23,000,000
(Gain) loss on hedged item in fair value hedge	1,000,000	5,000,000	-25,000,000	15,000,000
Deferred, net after-tax gains on derivative instruments			9,000,000
Cash and equivalents	2,376,000,000	3,191,000,000	2,376,000,000	3,191,000,000	3,270,000,000	2,905,000,000
Money market funds, at carrying value	1,100,000,000		1,100,000,000
Weighted average probability			55.00%
Available for sale equity securities amortized cost basis	91,000,000		91,000,000		13,000,000
Available for sale equity securities fair value	110,000,000		110,000,000		15,000,000
Available for sale securities cumulative unrealized gain (losses)	19,000,000		19,000,000		2,000,000													1,000,000	1,000,000
Losses recognized related to realized an unrealized losses associated with the company's Greek government and European Financial Stability Facility bonds					($8,000,000)

Summary_of_Gains_and_Losses_on

Summary of Gains and Losses on Derivative Instruments (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Fair Value Hedges | Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income, fair value hedges	$1	$5	($25)	$15
Not Designated as Hedging Instrument | Other (income) expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income, undesignated derivative instruments	51	-2	6	-13
Cash Flow Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in OCI	6	-24	68	-25
Gain (loss) reclassified from AOCI into income	8	4	36	2
Cash Flow Hedges | Interest Rate Contract
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in OCI		-3	26	-12
Gain (loss) reclassified from AOCI into income	-1		10
Cash Flow Hedges | Foreign Exchange Contracts One
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in OCI	-1	-1	-1	-2
Gain (loss) reclassified from AOCI into income		-1	-1	-2
Cash Flow Hedges | Foreign Exchange Contracts Two
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in OCI	7	-20	43	-11
Gain (loss) reclassified from AOCI into income	$9	$5	$27	$4

Classification_and_Fair_Value_

Classification and Fair Value Amounts of Derivative Instruments (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	$96	$142
Derivative liability, fair value	8	37
Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	96	95
Derivative liability, fair value	7	26
Designated as Hedging Instrument | Interest Rate Contract | Accounts Payable And Accrued Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value		21
Designated as Hedging Instrument | Interest Rate Contract | Other Long -Term Assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	42	67
Designated as Hedging Instrument | Foreign Exchange Contract | Accounts Payable And Accrued Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	6	5
Designated as Hedging Instrument | Foreign Exchange Contract | Other Long -Term Assets
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	8
Designated as Hedging Instrument | Foreign Exchange Contract | Prepaid Expense And Other
Derivatives, Fair Value [Line Items]
Derivative asset, fair value	46	28
Designated as Hedging Instrument | Foreign Exchange Contract | Other Long -Term Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	1
Not Designated as Hedging Instrument | Foreign Exchange Contract | Accounts Payable And Accrued Liabilities
Derivatives, Fair Value [Line Items]
Derivative liability, fair value	1	11
Not Designated as Hedging Instrument | Foreign Exchange Contract | Prepaid Expense And Other
Derivatives, Fair Value [Line Items]
Derivative asset, fair value		$47

Derivative_Positions_Presented

Derivative Positions Presented On Net Basis (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Derivatives, Fair Value [Line Items]
Gross amounts recognized in the consolidated balance sheet	$96	$142
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet	-8	-37
Total	88	105
Gross amounts recognized in the consolidated balance sheet	8	37
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet	-8	-37
Total

Financial_Assets_and_Liabiliti

Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Equity securities	$110	$15
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Foreign currency hedges, assets at fair value	54	75
Interest rate hedges, assets at fair value	42	67
Equity securities	110	15
Total assets	223	224
Foreign currency hedges, liabilities at fair value	8	16
Interest rate hedges, liabilities at fair value		21
Contingent payments related to acquisitions, liabilities at fair value	344	86
Total liabilities	352	123
Fair Value, Measurements, Recurring | Preferred Stock
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Debt securities		51
Fair Value, Measurements, Recurring | Foreign Government Debt Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Debt securities	17	16
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Equity securities	110	15
Total assets	110	15
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Foreign currency hedges, assets at fair value	54	75
Interest rate hedges, assets at fair value	42	67
Total assets	113	158
Foreign currency hedges, liabilities at fair value	8	16
Interest rate hedges, liabilities at fair value		21
Total liabilities	8	37
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2 | Foreign Government Debt Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Debt securities	17	16
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets		51
Contingent payments related to acquisitions, liabilities at fair value	344	86
Total liabilities	344	86
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3 | Preferred Stock
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Debt securities		$51

Reconciliation_of_Fair_Value_M

Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Level 3) (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent payments, fair value as of beginning of period	$86
Contingent payments, additions	269
Contingent payments, payments	-2
Contingent payments, unrealized gains recognized in earnings	-9
Contingent payments, fair value as of end of period	344
Preferred stock, fair value as of beginning of period	51
Preferred stock, Conversion to a publicly traded equity security	($51)

Book_Values_and_Fair_Values_of

Book Values and Fair Values of Financial Instruments (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]
Long-term debt and lease obligations	$8,652	$5,580
Book Values
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]
Long-term insurance receivables	2	2
Investments	52	46
Short-term debt	42	27
Current maturities of long-term debt and lease obligations	372	323
Long-term debt and lease obligations	8,652	5,580
Long-term litigation liabilities	53	32
Approximate Fair Values
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]
Long-term insurance receivables	2	2
Investments	53	49
Short-term debt	42	27
Current maturities of long-term debt and lease obligations	377	324
Long-term debt and lease obligations	8,930	6,201
Long-term litigation liabilities	$52	$31

Summarization_of_Bases_Used_to

Summarization of Bases Used to Measure Fair Value of Financial Instruments (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt and lease obligations	$8,652	$5,580
Approximate Fair Values
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term insurance receivables	2	2
Investments	53	49
Total assets	55	51
Short-term debt	42	27
Current maturities of long-term debt and lease obligations	377	324
Long-term debt and lease obligations	8,930	6,201
Long-term litigation liabilities	52	31
Total liabilities	9,401	6,583
Fair Value, Inputs, Level 2 | Approximate Fair Values
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term insurance receivables	2	2
Investments	18	19
Total assets	20	21
Short-term debt	42	27
Current maturities of long-term debt and lease obligations	377	324
Long-term debt and lease obligations	8,930	6,201
Long-term litigation liabilities	52	31
Total liabilities	9,401	6,583
Fair Value, Inputs, Level 3 | Approximate Fair Values
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investments	35	30
Total assets	$35	$30

Shareholders_Equity_Additional

Shareholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended				3 Months Ended		9 Months Ended
	Jul. 31, 2013	31-May-13	Mar. 31, 2013	Jul. 31, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stockholders Equity Note [Line Items]
Stock compensation expense					$39,000,000	$34,000,000	$111,000,000	$97,000,000
Stock based compensation in marketing and administrative expenses					70.00%	70.00%	70.00%	70.00%
Stock Options granted			6,200,000
Performance condition to percentage of PSU's							50.00%
Cash dividend payments							757,000,000	558,000,000
Percentage of increase in dividend over the previously quarterly rate		9.00%		34.00%
Cash dividends declared per common share	$0.49	$0.49		$0.45	$0.49	$0.45	$1.43	$1.12
Share repurchases					2,000,000		12,400,000
Value of share repurchases					145,000,000		863,000,000
Stock repurchase program, authorized amount				2,000,000,000
Remaining value available under stock repurchase programs							1,100,000,000
Stock Options
Stockholders Equity Note [Line Items]
Total intrinsic value of stock options exercised					60,000,000	34,000,000	167,000,000	67,000,000
Unrecognized compensation cost related to all unvested					74,000,000		74,000,000
Weighted-average period for all unvested							1 year 7 months 6 days
Senior Management | Performance Based Awards With Market Conditions
Stockholders Equity Note [Line Items]
Performance condition to percentage of PSU's							50.00%
Restricted Stock Units
Stockholders Equity Note [Line Items]
Awards Granted			852,000
Unrecognized compensation cost related to all unvested					82,000,000		82,000,000
Weighted-average period for all unvested							1 year 10 months 24 days
Performance Shares
Stockholders Equity Note [Line Items]
Awards Granted			376,000
Unrecognized compensation cost related to all unvested					$20,000,000		$20,000,000
Weighted-average period for all unvested							1 year 3 months 18 days

Stock_Options_Fair_Value_Assum

Stock Options Fair Value Assumptions (Detail) (Stock Option, USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	25.00%	25.00%
Expected life (in years)	5 years 6 months	5 years 6 months
Risk-free interest rate	0.90%	1.00%
Dividend yield	2.60%	2.30%
Fair value per stock option	$12	$10

Performance_Stock_Units_Fair_V

Performance Stock Units Fair Value Assumptions (Detail) (Performance Shares, USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Baxter volatility	21.00%	24.00%
Peer group volatility
Peer group volatility minimum	13.00%	14.00%
Peer group volatility maximum	38.00%	50.00%
Correlation of returns
Correlation of returns minimum	0.37	0.26
Correlation of returns maximum	0.62	0.54
Risk-free interest rate	0.30%	0.40%
Fair value per PSU	$67	$72

Net_Periodic_Benefit_Cost_Deta

Net Periodic Benefit Cost (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Pension Plans, Defined Benefit
Net periodic benefit cost
Service cost	$34	$28	$101	$83
Interest cost	52	58	154	176
Expected return on plan assets	-63	-72	-190	-216
Amortization of net losses and other deferred amounts	61	52	184	156
Net periodic benefit cost	84	66	249	199
Other Postretirement Benefit Plans, Defined Benefit
Net periodic benefit cost
Service cost	2	2	7	5
Interest cost	6	8	19	22
Amortization of net loss and prior service credit	3	1	7	5
Net periodic benefit cost	$11	$11	$33	$32

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Taxes [Line Items]
Effective income tax rate	20.20%	23.90%	20.40%	20.90%
Tax and legal reserves associated with VAT matters in Turkey	$104
Currency related charges			52
Infusion pump reserve adjustment				37
Reduction in gross unrecognized tax benefits	$153		$153

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail) (USD $)	Sep. 30, 2013	Aug. 31, 2013	Aug. 31, 2013	Aug. 31, 2013	Mar. 31, 2012	Sep. 30, 2013	Oct. 31, 2013
In Millions, unless otherwise specified		DerivativeAction	Illinois State	Delaware	Hemodialysis Litigation	Heparin Litigation	Subsequent Event
			DerivativeAction	DerivativeAction		Case
Loss Contingencies [Line Items]
Total legal liabilities	$160
Litigation related receivables	9
Royalties awarded					9
Past damages and interest awarded					20
Lawsuits pending						130
Number of derivative actions filed in state court		2	1	1
Settlement of claims announced by co-defendant							$64

Segment_Information_Additional

Segment Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013
	Segment
Segment Information [Line Items]
Number of segments	2

Financial_Information_for_Comp

Financial Information for Company's Segments (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Information [Line Items]
Net sales	$3,774	$3,477	$10,891	$10,437
Pre-tax income	958	925	2,889	2,819
BioScience
Segment Information [Line Items]
Net sales	1,620	1,522	4,788	4,550
Pre-tax income	615	537	1,851	1,605
Medical Products
Segment Information [Line Items]
Net sales	2,154	1,955	6,103	5,887
Pre-tax income	$343	$388	$1,038	$1,214

PreTax_Income_Reconciliation_D

Pre-Tax Income Reconciliation (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$682	$766	$2,118	$2,315
Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	958	925	2,889	2,819
Unallocated Amount To Segment Stock Compensation
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	-39	-34	-111	-97
Unallocated Amount To Segment Net Interest Expense
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	-45	-25	-87	-65
Unallocated Amount To Segment Certain Foreign Currency Fluctuations and Hedging Activities
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	21	13	63	33
Unallocated Amount To Segment Certain Tax And Legal Reserves
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	-104		-104
Unallocated Amount to Segment Other Corporate Items
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	($109)	($113)	($532)	($375)